ASHISH KAMAT

TitleProfessor
InstitutionMD Anderson
DepartmentUrology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Leary JB, Enright T, Bakaloudi DR, Basnet A, Bratslavsky G, Jacob J, Spiess PE, Li R, Necchi A, Kamat AM, Pavlick DC, Danziger N, Huang RSP, Lin DI, Cheng L, Ross J, Talukder R, Grivas P. Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer. Target Oncol. 2024 Apr 03. PMID: 38570422.
      Citations:    Fields:    
    2. Myers AA, Tan WS, de Groot J, Westney OL, Kamat AM. 'Case of the Month' from The University of Texas MD Anderson Cancer Center, Houston, Texas, USA: ependymoma of the urinary bladder. BJU Int. 2024 Feb 20. PMID: 38379218.
      Citations:    Fields:    
    3. Contieri R, Tan WS, Grajales V, Hensley PJ, Martini A, Bree K, Myers A, Nogueras-Gonzalez G, Navai N, Dinney CP, Guo C, Kamat AM. Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy. BJU Int. 2024 Feb 19. PMID: 38374533.
      Citations:    Fields:    
    4. Myers AA, Kamat AM, Kilbert A, Galsky MD. Toward standardization in bladder cancer clinical trials: Guidance from the SITC-IBCG expert panel. J Immunother Cancer. 2024 Feb 02; 12(2). PMID: 38309724; PMCID: PMC10840062.
      Citations:    Fields:    Translation:Humans
    5. Myers AA, Kamat AM. Statins and BCG response: Is there more to the story? Scott Med J. 2024 Feb; 69(1):1-2. PMID: 38557231.
      Citations:    Fields:    Translation:Humans
    6. Lotan Y, Agarwal P, Black P, Dickstein R, Kamat AM, Lee B, Narayan VM, Porten S, Psutka SP, Smith AK, Svatek RS, Williams SB, Woldu S. Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials. Urol Oncol. 2024 Feb 01. PMID: 38307803.
      Citations:    Fields:    
    7. Lobo N, Duan Z, Sood A, Tan WS, Grajales V, Contieri R, Lindskrog SV, Dyrskj?t L, Zhao H, Giordano SH, Williams SB, Bree KK, Kamat AM. Association of Age with Non-muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities? Eur Urol Oncol. 2024 Jan 31. PMID: 38302322.
      Citations: 1     Fields:    
    8. Necchi A, Posada JM, Yakirevich E, Kamat AM, Sood A, Jacob JM, Bratslavsky G, Grivas P, Spiess PE, Li R, Mega AE, Golijanin DJ, Pavlick D, Huang RSP, Lin D, Danziger N, Sokol ES, Sivakumar S, Ross JS, Cheng L. Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2. Mod Pathol. 2024 Mar; 37(3):100424. PMID: 38219954.
      Citations:    Fields:    Translation:Humans
    9. Bochner BH, Kamat AM, Bivalacqua TJ. Open vs Robotic Cystectomy: Case Closed? J Urol. 2024 Mar; 211(3):473-475. PMID: 38109705.
      Citations:    Fields:    Translation:Humans
    10. Gore JL, Follmer K, Reynolds J, Nash M, Anderson CB, Catto JWF, Chamie K, Daneshmand S, Dickstein R, Garg T, Gilbert SM, Guzzo TJ, Kamat AM, Kates MR, Lane BR, Lotan Y, Mansour AM, Master VA, Montgomery JS, Morris DS, Nepple KG, O'Neil BB, Patel S, Pohar K, Porten SP, Riggs SB, Sankin A, Scarpato KR, Shore ND, Steinberg GD, Strope SA, Taylor JM, Comstock BA, Kessler LG, Wolff EM, Smith AB. Interruptions in bladder cancer care during the COVID-19 public health emergency. Urol Oncol. 2024 04; 42(4):116.e17-116.e21. PMID: 38087711.
      Citations:    Fields:    Translation:HumansPHPublic Health
    11. Myers AA, Briganti A, Leibovich B, Lerner SP, Moschini M, Roupr?t M, Shariat SF, Spiess PE, Stenzl A, Taneja SS, Touijer KA, Kamat AM. Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023? Eur Urol Oncol. 2023 Nov 16. PMID: 37980250.
      Citations:    Fields:    
    12. Sood A, Rudzinski JK, Labbate CV, Hensley PJ, Bree KK, Guo CC, Alhalabi O, Campbell MT, Siefker-Radtke AO, Navai N, Dinney CPN, Gao J, Kamat AM. Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience. J Urol. 2024 Feb; 211(2):241-255. PMID: 37922370.
      Citations:    Fields:    Translation:Humans
    13. Hensley PJ, Choudhury A, Khaki AR, Grivas P, Kamat AM. The 2023 European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: A Critical Appraisal. Eur Urol. 2024 01; 85(1):32-34. PMID: 37919189.
      Citations:    Fields:    Translation:Humans
    14. Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AO. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol. 2023 12; 6(6):611-620. PMID: 37833193.
      Citations:    Fields:    Translation:Humans
    15. Liu K, Zhao H, Chen X, Nicoletti R, Vasdev N, Chiu PK, Ng CF, Kawada T, Laukhtina E, Mori K, Yanagisawa T, D'Andrea D, von Deimling M, Albisinni S, Krajewski W, Pradere B, Soria F, Moschini M, Enikeev D, Shariat S, Kamat A, Giannarini G, Teoh JY, European Association of Urology?Young Academic Urologists Urothelial Carcinoma Working Group. A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Gu?rin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023 Oct 10. PMID: 37827948.
      Citations: 2     Fields:    
    16. Ghelani GH, Zerdan MB, Jacob J, Spiess PE, Li R, Necchi A, Grivas P, Kamat A, Danziger N, Lin D, Huang R, Decker B, Sokol ES, Cheng L, Pavlick D, Ross JS, Bratslavsky G, Basnet A. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study. Urol Oncol. 2023 12; 41(12):486.e15-486.e23. PMID: 37821306.
      Citations:    Fields:    Translation:Humans
    17. Contieri R, Hensley PJ, Kamat AM. Reply to Francesco Montorsi, Giuseppe Rosiello, and Giorgio Gandaglia's Letter to the Editor re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Gu?rin or Early Radical Cystectomy. Eur Urol Oncol. 2023;6:590-596. Eur Urol Oncol. 2024 Apr; 7(2):301. PMID: 37806840.
      Citations:    Fields:    Translation:HumansCells
    18. Kamat AM, Apolo AB, Babjuk M, Bivalacqua TJ, Black PC, Buckley R, Campbell MT, Comp?rat E, Efstathiou JA, Grivas P, Gupta S, Kurtz NJ, Lamm D, Lerner SP, Li R, McConkey DJ, Palou Redorta J, Powles T, Psutka SP, Shore N, Steinberg GD, Sylvester R, Witjes JA, Galsky MD. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. J Clin Oncol. 2023 Dec 10; 41(35):5437-5447. PMID: 37793077; PMCID: PMC10713193.
      Citations: 2     Fields:    Translation:Humans
    19. DiNardo AR, Arditi M, Kamat AM, Koster KJ, Carrero S, Nishiguchi T, Lebedev M, Benjamin AB, Avalos P, Lozano M, Moule MG, McCune B, Herron B, Ladki M, Sheikh D, Spears M, Herrejon IA, Dodge C, Kumar S, Hutchison RW, Ofili TU, Opperman LA, Bernard JA, Lerner SP, Udeani G, Neal G, Netea MG, Cirillo JD. Bacillus Calmette-Gu?rin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responses. Trials. 2023 Oct 04; 24(1):636. PMID: 37794431; PMCID: PMC10548680.
      Citations: 1     Fields:    Translation:HumansCellsPHPublic Health
    20. Tan WS, Hall E, Kamat AM, Kelly JD. Clinical trial design for non-muscle-invasive bladder cancer. Nat Rev Urol. 2023 10; 20(10):575-576. PMID: 37328547.
      Citations:    Fields:    Translation:Humans
    21. Tan WS, Contieri R, Buffi NM, Lughezzani G, Grajales V, Soloway M, Casale P, Hurle R, Kamat AM. Reply by Authors. J Urol. 2023 Nov; 210(5):770. PMID: 37622536.
      Citations:    Fields:    
    22. Basile G, Pradere B, Bellmunt J, Roupr?t M, Kamat AM, Seisen T. A Plea for the Use of Video-recorded Cystoscopy for Blinded Independent Central Review of Tumor Response in Open-label Non-muscle invasive Bladder Cancer Trials. Eur Urol Oncol. 2023 Oct; 6(5):453-455. PMID: 37604762.
      Citations:    Fields:    
    23. Contieri R, Hensley PJ, Tan WS, Grajales V, Bree K, Nogueras-Gonzalez GM, Lee BH, Navai N, Dinney CP, Kamat AM. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Gu?rin or Early Radical Cystectomy. Eur Urol Oncol. 2023 12; 6(6):590-596. PMID: 37558542.
      Citations:    Fields:    Translation:Humans
    24. Tan WS, Contieri R, Buffi NM, Lughezzani G, Grajales V, Soloway M, Casale P, Hurle R, Kamat AM. International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance. J Urol. 2023 Nov; 210(5):763-770. PMID: 37535836.
      Citations:    Fields:    
    25. Contieri R, Grajales V, Tan WS, Martini A, Sood A, Hensley P, Bree K, Navai N, Dinney CP, Kamat AM, Lobo N, Nogueras-Gonzalez GM, Guo CC. Impact of age >70?years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Gu?rin. BJU Int. 2024 01; 133(1):63-70. PMID: 37442564; PMCID: PMC10787034.
      Citations: 2     Fields:    Translation:Humans
    26. Tan WS, McElree IM, Davaro F, Steinberg RL, Bree K, Navai N, Dinney CP, O'Donnell MA, Li R, Kamat AM, Packiam VT. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Gu?rin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023 10; 6(5):531-534. PMID: 37468392.
      Citations:    Fields:    Translation:Humans
    27. Rose KM, Huelster HL, Meeks JJ, Faltas BM, Sonpavde GP, Lerner SP, Ross JS, Spiess PE, Grass GD, Jain RK, Kamat AM, Vosoughi A, Wang L, Wang X, Li R. Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease. Nat Rev Urol. 2023 Jul; 20(7):452. PMID: 37217696.
      Citations: 1     Fields:    
    28. Paner GP, Kamat A, Netto GJ, Samaratunga H, Varma M, Bubendorf L, van der Kwast TH, Cheng L, Members of the ISUP Bladder Tumor Consensus Panel. International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: Grading of Mixed Grade, Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent Differentiations, and Non-Urothelial Carcinomas. Am J Surg Pathol. 2024 Jan 01; 48(1):e11-e23. PMID: 37382156.
      Citations: 1     Fields:    Translation:Humans
    29. Tan WS, Grajales V, Bree K, Li R, Nogueras-Gonzalez GM, Navai N, Dinney C, Kamat AM. Bacillus Calmette-Gu?rin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal? BJU Int. 2023 10; 132(4):384-386. PMID: 37246493.
      Citations:    Fields:    Translation:HumansCells
    30. Crupi E, de Padua TC, Marandino L, Raggi D, Dyrskj?t L, Spiess PE, Sonpavde GP, Kamat AM, Necchi A. Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review. Eur Urol Oncol. 2024 Feb; 7(1):44-52. PMID: 37330413.
      Citations:    Fields:    
    31. Makaroff LE, Filicevas A, Boldon S, Hensley P, Black PC, Chisolm S, Demkiw S, Fern?ndez MI, Sugimoto M, Jensen BT, Witjes WPJ, Bagshaw K, Cirefice-Funk L, Knight A, Kamat AM. Patient and Carer Experiences with Bladder Cancer: Results from a Global Survey in 45 Countries. Eur Urol. 2023 08; 84(2):248-251. PMID: 37236857.
      Citations: 1     Fields:    Translation:Humans
    32. Bree KK, Kokorovic A, Westerman ME, Hensley PJ, Brooks NA, Qiao W, Shen Y, Kamat AM, Dinney CP, Navai N. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply. J Urol. 2023 08; 210(2):254-255. PMID: 37211780.
      Citations:    Fields:    Translation:Humans
    33. Jubber I, Ong S, Bukavina L, Black PC, Comp?rat E, Kamat AM, Kiemeney L, Lawrentschuk N, Lerner SP, Meeks JJ, Moch H, Necchi A, Panebianco V, Sridhar SS, Znaor A, Catto JWF, Cumberbatch MG. Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors. Eur Urol. 2023 08; 84(2):176-190. PMID: 37198015.
      Citations: 5     Fields:    Translation:HumansPHPublic Health
    34. Tan WS, Grajales V, Contieri R, Hensley P, Bree K, Msaouel P, Guo CC, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes. Eur Urol Open Sci. 2023 Jul; 53:16-22. PMID: 37441349; PMCID: PMC10334230.
      Citations: 2     
    35. Beijert IJ, Cheng L, Liedberg F, Plass K, Williamson SR, Gontero P, Ribal MJ, Babjuk M, Black PC, Kamat AM, Algaba F, Berman DM, Hartmann A, Masson-Lecomte A, Roupr?t M, Lopez-Beltran A, Samaratunga H, Shariat SF, Mostafid AH, Varma M, Shen S, Burger M, Tsuzuki T, Palou J, Comp?rat EM, Sylvester RJ, van der Kwast TH, van Rhijn BWG, Downes MR. International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members. Eur Urol Open Sci. 2023 Jun; 52:154-165. PMID: 37284047; PMCID: PMC10240524.
      Citations:    
    36. Koti M, Bivalacqua T, Black PC, Cathomen T, Galsky MD, Gulley JL, Ingersoll MA, Kamat AM, Kassouf W, Siemens DR, Gao J. Adaptive Immunity in Genitourinary Cancers. Eur Urol Oncol. 2023 06; 6(3):263-272. PMID: 37069029.
      Citations:    Fields:    Translation:Humans
    37. Rose KM, Huelster HL, Meeks JJ, Faltas BM, Sonpavde GP, Lerner SP, Ross JS, Spiess PE, Grass GD, Jain RK, Kamat AM, Vosoughi A, Wang L, Wang X, Li R. Circulating and urinary tumour DNA in urothelial carcinoma?- upper tract, lower tract and metastatic disease. Nat Rev Urol. 2023 07; 20(7):406-419. PMID: 36977797.
      Citations:    Fields:    Translation:Humans
    38. Tan WS, Tan MY, Alhalabi O, Campbell MT, Kamat AM, Gao J. Evolving systemic management of urothelial cancers. Curr Opin Oncol. 2023 05 01; 35(3):186-199. PMID: 36966497.
      Citations: 1     Fields:    Translation:Humans
    39. Hurle R, Soria F, Contieri R, Avolio PP, Mancon S, Lazzeri M, Bernasconi V, Mazzoli S, Pizzuto G, De Bellis M, Rosazza M, Livoti S, Lupia T, Corcione S, Lillaz B, De Rosa FG, Buffi NM, Kamat AM, Gontero P, Casale P. Evaluating the Protective Effect of Intravesical Bacillus Calmette-Guerin against SARS-CoV-2 in Non-Muscle Invasive Bladder Cancer Patients: A Multicenter Observational Trial. Cancers (Basel). 2023 Mar 06; 15(5). PMID: 36900409; PMCID: PMC10000457.
      Citations: 1     
    40. Hensley PJ, Seiler R, Herr H, Mouw KW, Iyer G, Dyrskj?t L, Nawroth R, Goebell P, Schmitz-Drager B, Todenhofer T, Black PC, Kamat AM, Williams SB. Bladder preservation after neoadjuvant therapy - 2021 IBCN updates part 1. Urol Oncol. 2023 07; 41(7):307-312. PMID: 36702704.
      Citations:    Fields:    Translation:Humans
    41. Goebell PJ, Kamat AM, Black PC, Dyrskj?t L, Nawroth R, Seiler R, Todenh?fer T, Williams SB, Schmitz-Dr?ger BJ. Editorial: Cutting edge basic and clinical bladder cancer research - the IBCN updates. Urol Oncol. 2023 07; 41(7):313-317. PMID: 36641302.
      Citations:    Fields:    Translation:Humans
    42. Dyrskj?t L, Vlahou A, Black PC, Droller M, Grossmann HB, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Todenh?fer T, Williams SB, Schmitz-Dr?ger BJ. 25 years International Bladder Cancer Network (IBCN): The past, the present, and the future. Urol Oncol. 2023 Jul; 41(7):302-306. PMID: 36437158.
      Citations:    Fields:    Translation:HumansPHPublic Health
    43. Christensen E, Wyatt AW, Galsky MD, Grivas P, Seiler R, Nawroth R, Goebell PJ, Schmitz-Drager BJ, Williams SB, Black PC, Kamat AM, Todenh?fer T, Dyrskj?t L. IBCN Seminar Series 2021: Circulating tumor DNA in bladder cancer. Urol Oncol. 2023 Jul; 41(7):318-322. PMID: 36437155.
      Citations:    Fields:    Translation:HumansCells
    44. Hensley PJ, Duan Z, Bree K, Sood A, Zhao H, Lobo N, Contieri R, Campbell MT, Guo CC, Navai N, Williams SB, Dinney CP, Kamat AM. Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy: Implications for survivorship. Urol Oncol. 2023 02; 41(2):108.e11-108.e17. PMID: 36404232.
      Citations:    Fields:    Translation:Humans
    45. Reike MJ, Ingersoll MA, M?ller DC, Zuiverloon TCM, Strandgaard T, Kamat AM, Williams SB, Seiler R, Todenh?fer T, Dyrskj?t L, Nawroth R, Goebell P, Schmitz-Dr?ger B, Sfakianos JP, Meeks J, Horowitz A, Black PC. Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III. Urol Oncol. 2023 05; 41(5):211-218. PMID: 36266219.
      Citations: 1     Fields:    Translation:Humans
    46. Necchi A, Joshi M, Bangs R, Makaroff L, Grivas P, Kamat AM, Kassouf W, Raggi D, Marandino L, Krupski T, Flaig TW, Spiess PE, Global Society of Rare Genitourinary Tumors (GSRGT) and the International Bladder Cancer Group (IBCG. Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract Cancer: Propagating Access, Policies and Resources Uniformly. Clin Genitourin Cancer. 2023 04; 21(2):301-308. PMID: 36344399.
      Citations:    Fields:    Translation:Humans
    47. Bree KK, Kokorovic A, Westerman ME, Hensley PJ, Brooks NA, Qiao W, Shen Y, Kamat AM, Dinney CP, Navai N. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but Not Therapeutic. J Urol. 2023 01; 209(1):140-149. PMID: 36250944.
      Citations: 1     Fields:    Translation:Humans
    48. Leow JJ, Tan WS, Tan WP, Tan TW, Chan VW, Tikkinen KAO, Kamat A, Sengupta S, Meng MV, Shariat S, Roupret M, Decaestecker K, Vasdev N, Chong YL, Enikeev D, Giannarini G, Ficarra V, Teoh JY, UroSoMe Collaborators. A systematic review and meta-analysis on delaying surgery for urothelial carcinoma of bladder and upper tract urothelial carcinoma: Implications for the COVID19 pandemic and beyond. Front Surg. 2022; 9:879774. PMID: 36268209; PMCID: PMC9577485.
      Citations: 1     
    49. Comp?rat E, Amin MB, Cathomas R, Choudhury A, De Santis M, Kamat A, Stenzl A, Thoeny HC, Witjes JA. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet. 2022 11 12; 400(10364):1712-1721. PMID: 36174585.
      Citations: 16     Fields:    Translation:Humans
    50. Sood A, Kamat AM. Editorial Commentary. Urol Pract. 2022 Sep; 9(5):404. PMID: 37145752.
      Citations:    
    51. Labbate CV, Hensley PJ, Miest TS, Qiao W, Adibi M, Shah AY, Chery L, Papadopoulos J, Siefker-Radtke AO, Gao J, Guo CC, Czerniak BA, Navai N, Kamat AM, Dinney CP, Campbell MT, Matin SF. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol. 2022 10; 40(10):454.e17-454.e23. PMID: 35961847.
      Citations:    
    52. Zaleski MP, Chen H, Roy-Chowdhuri S, Patel KP, Luthra R, Routbort MJ, Kamat AM, Gao J, Siefker-Radtke A, Czerniak B, Guo CC. Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma. Am J Clin Pathol. 2022 08 04; 158(2):263-269. PMID: 35467000; PMCID: PMC9350833.
      Citations:    Fields:    
    53. Bree KK, Hensley PJ, Lobo N, Brooks NA, Nogueras-Gonzalez GM, Guo CC, Navai N, Grossman HB, Dinney CP, Kamat AM. Reply by Authors. J Urol. 2022 08; 208(2):290-291. PMID: 35770497.
      Citations:    Fields:    
    54. Bree KK, Hensley PJ, Lobo N, Brooks NA, Nogueras-Gonzalez GM, Guo CC, Navai N, Grossman HB, Dinney CP, Kamat AM. All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Gu?rin Response in High-Grade Ta Tumors. J Urol. 2022 08; 208(2):284-291. PMID: 35770498.
      Citations:    Fields:    Translation:HumansCells
    55. Pohar KS, Patel S, Lotan Y, Trabulsi E, Woods M, Downs T, Huang WC, Jones J, Taylor J, O'Donnell M, Bivalacqua TJ, DeCastro J, Steinberg G, Kamat AM, Resnick MJ, Konety B, Schoenberg M, Jones JS, Daneshmand S, Flexible Blue Light Study Group Collaborators. Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study. Urol Oncol. 2022 08; 40(8):382.e1-382.e6. PMID: 35750559.
      Citations:    Fields:    Translation:Humans
    56. Tan WS, Steinberg G, Witjes JA, Li R, Shariat SF, Babjuk M, Bivalacqua TJ, Psutka SP, Williams SB, Cookson MS, Kamat AM, Roupret M, Palou J. Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol. 2022 10; 5(5):505-516. PMID: 35718695.
      Citations:    Fields:    
    57. Freudenburg E, Bagheri I, Srinivas S, Martinez A, Putluri N, Klaassen Z, Kamat AM, Konety BR, Kim WY, McConkey DJ, Freedland SJ, Black PC, Daneshmand S, Catto JWF, Williams SB, Dyrskj?t L. Race reporting and disparities regarding clinical trials in bladder cancer: a systematic review. Cancer Causes Control. 2022 Aug; 33(8):1071-1081. PMID: 35699798.
      Citations:    Fields:    Translation:Humans
    58. Hensley PJ, Panebianco V, Pietzak E, Kutikov A, Vikram R, Galsky MD, Shariat SF, Roupret M, Kamat AM. Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations. Eur Urol Oncol. 2022 08; 5(4):403-411. PMID: 35581143.
      Citations:    Fields:    
    59. Agrawal P, Baraban E, de la Calle C, Patel S, Kamat AM, Smith A. Primary mesonephric adenocarcinoma of the bladder: A case report. Urol Case Rep. 2022 Jul; 43:102096. PMID: 35520026; PMCID: PMC9062416.
      Citations:    
    60. Teoh JY, Kamat AM, Black PC, Grivas P, Shariat SF, Babjuk M. Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective. Nat Rev Urol. 2022 05; 19(5):280-294. PMID: 35361927.
      Citations:    Fields:    Translation:Humans
    61. Laukhtina E, Moschini M, Soria F, Andrea DD, Teoh JY, Mori K, Mari A, Krajewski W, Cimadamore A, Abufaraj M, Enikeev D, Giannarini G, Kamat AM, Babjuk M, Witjes JA, Shariat SF, Pradere B, European Association of Urology, Young Academic Urologists EAU-YAU: Urothelial Carcinoma Working Group, European Association of Urology Section of Oncological Urology ESOU, Albisinni S, Neuzillet Y, Xylinas E, Roupret M. Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group. Eur Urol Focus. 2022 Mar 22. PMID: 35337773.
      Citations:    Fields:    
    62. Bree KK, Shan Y, Hensley PJ, Lobo N, Hu C, Tyler DS, Chamie K, Kamat AM, Williams SB. Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non-Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013. JAMA Netw Open. 2022 03 01; 5(3):e223050. PMID: 35302627; PMCID: PMC8933744.
      Citations:    Fields:    Translation:Humans
    63. Lobo N, Martini A, Kamat AM. Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2022 04; 22(4):361-370. PMID: 35212590.
      Citations:    Fields:    Translation:Humans
    64. Golla V, Shan Y, Farran EJ, Stewart CA, Vu K, Yu A, Khaki AR, Parikh DA, Swanson TA, Keegan KA, Kamat AM, Tyler DS, Freedland SJ, Williams SB. Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. Urol Oncol. 2022 06; 40(6):273.e1-273.e9. PMID: 35168881.
      Citations: 1     Fields:    Translation:Humans
    65. Freudenburg E, Shan Y, Martinez A, Srinivasan A, Movva G, Yu A, AlBayyaa M, Klaassen Z, Freedland SJ, Kamat AM, Williams SB. Geographic distribution of racial differences in mortality in muscle-invasive bladder cancer patients: an opportunity for improvement. Cancer Causes Control. 2022 Apr; 33(4):613-622. PMID: 35050417.
      Citations: 1     Fields:    Translation:Humans
    66. Laukhtina E, Shim SR, Mori K, D'Andrea D, Soria F, Rajwa P, Mostafaei H, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Lotan Y, Gontero P, Babjuk M, Witjes JA, Kamat AM, Shariat SF, Pradere B, Comp?rat E, Xylinas E, Palou J, Roupret M, European Association of Urology?Young Academic Urologists EAU-YAU Urothelial Carcinoma Working Group. Corrigendum to "Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis" [Eur Urol Oncol 2021;4:927-42]. Eur Urol Oncol. 2022 Aug; 5(4):480-481. PMID: 35063436.
      Citations:    Fields:    
    67. Hensley PJ, Kamat AM. Re: Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022 03; 81(3):316-317. PMID: 35039182.
      Citations:    Fields:    Translation:Humans
    68. Murakami K, Kamat AM, Dai Y, Pagano I, Chen R, Sun Y, Gupta A, Goodison S, Rosser CJ, Furuya H. Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study. Cancer Biomark. 2022; 33(1):151-157. PMID: 34511488; PMCID: PMC8925124.
      Citations:    Fields:    Translation:Humans
    69. Adibi M, McCormick B, Economides MP, Petros F, Xiao L, Guo C, Shah A, Kamat AM, Dinney C, Navai N, Gao J, Siefker-Radtke A, Matin SF, Campbell MT. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer. 2022 04; 20(2):176-182. PMID: 35039231.
      Citations:    Fields:    Translation:Humans
    70. Kamat AM, Bivalacqua TJ, Lerner SP, Kassouf W, Brausi M, Buckley R, Persad R, Lamm D, Soloway M, Brothers K, Steinberg G, Lotan Y, Sylvester R, Alfred Witjes J, Black PC, Roumigui? M, B?hle A, Colombel M, Palou-Redorta J. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Gu?rin-exposed High-risk Non-muscle-invasive Bladder Cancer. Eur Urol. 2022 07; 82(1):34-46. PMID: 34955291.
      Citations:    Fields:    Translation:Humans
    71. Mitra AP, Narayan VM, Mokkapati S, Miest T, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown GA, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Philipson R, Sawutz D, Parker NR, McConkey DJ, Dinney CPN, Yl?-Herttuala S. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228. PMID: 34933753; PMCID: PMC8891058.
      Citations:    Fields:    Translation:Humans
    72. Lobo N, Hensley PJ, Bree KK, Nogueras-Gonzalez GM, Navai N, Dinney CP, Sylvester RJ, Kamat AM. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Gu?rin. Eur Urol Oncol. 2022 02; 5(1):84-91. PMID: 34920986.
      Citations:    Fields:    Translation:Humans
    73. Lobo N, Bree KK, Hensley PJ, Nogueras-Gonzalez GM, Abraham P, Navai N, Dinney CP, Kamat AM. Reduced-dose bacillus Calmette-Gu?rin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre. BJU Int. 2022 09; 130(3):323-330. PMID: 34847263.
      Citations:    Fields:    
    74. Lobo N, Hensley PJ, Bree KK, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. Should patients with non-muscle-invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette-Gu?rin? BJU Int. 2022 10; 130(4):463-469. PMID: 34854189.
      Citations:    Fields:    
    75. Hensley PJ, Bree KK, Guo CC, Lobo N, Campbell MT, Pettaway CA, Kamat AM. Clinicopathological analysis and outcomes of inflammatory myofibroblastic tumours of the urinary bladder. BJU Int. 2022 11; 130(5):604-610. PMID: 34773684.
      Citations:    Fields:    
    76. Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang RM, Shah AY, Campbell MT, Holla V, Kamat A, Wang WL, Wang J, Chen J, Meng J, Zhang M, Bondaruk J, Titus M, Genovese G, Czerniak BA, Shaw KR, Meric-Bernstam F, Guo CC, Logothetis CJ, Siefker-Radtke A, Msaouel P, Wang L, Liu J, Gao J. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol. 2023 04; 6(2):228-232. PMID: 34789422; PMCID: PMC9106763.
      Citations: 4     Fields:    
    77. Laukhtina E, Shim SR, Mori K, D'Andrea D, Soria F, Rajwa P, Mostafaei H, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Lotan Y, Gontero P, Babjuk M, Witjes JA, Kamat AM, Shariat SF, Pradere B, Comp?rat E, Xylinas E, Palou J, Roupret M, European Association of Urology?Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Gr. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. Eur Urol Oncol. 2021 12; 4(6):927-942. PMID: 34753702.
      Citations: 4     Fields:    Translation:Humans
    78. Khanna A, Miest T, Sharma V, Campbell R, Hensley P, Thapa P, Zganjar A, Tollefson MK, Thompson RH, Frank I, Karnes RJ, Murthy PB, Haber GP, Navai N, Kamat AM, Dinney C, Lee B, Boorjian SA. Role of Lymphadenectomy during Radical Cystectomy for Nonmuscle-Invasive Bladder Cancer: Results from a Multi-Institutional Experience. J Urol. 2022 Mar; 207(3):551-558. PMID: 34694143.
      Citations:    Fields:    Translation:Humans
    79. Alhalabi O, Campbell MT, Xiao L, Adriazola AC, Wilson NR, Siefker-Radtke AO, Corn PG, Zurita A, Jonasch E, Gao J, Adibi M, Kamat AM, Navai N, Pisters LL, Dinney C, Matin SF, Shah AY. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass. 2022 Jan; 3(1):37-44. PMID: 35475152; PMCID: PMC8988842.
      Citations: 2     
    80. Chang E, Apolo AB, Bangs R, Chisolm S, Duddalwar V, Efstathiou JA, Goldberg KB, Hansel DE, Kamat AM, Kluetz PG, Lerner SP, Plimack E, Prowell T, Singh H, Suzman D, Yu EY, Zhang H, Beaver JA, Pazdur R, Weinstock C, Galsky MD. Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop. Nat Rev Urol. 2022 01; 19(1):37-46. PMID: 34508246.
      Citations:    Fields:    Translation:Humans
    81. Hensley PJ, Kamat AM. Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Gu?rin: Implications for Clinical Trial Design. Reply. J Urol. 2021 Dec; 206(6):1528. PMID: 34520231.
      Citations:    Fields:    
    82. Balar AV, Kamat AM, de Wit R, KEYNOTE-057 investigators. Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer - Authors' reply. Lancet Oncol. 2021 09; 22(9):e380. PMID: 34478664.
      Citations:    Fields:    Translation:Humans
    83. Russo GI, Sholklapper TN, Cocci A, Broggi G, Caltabiano R, Smith AB, Lotan Y, Morgia G, Kamat AM, Witjes JA, Daneshmand S, Desai MM, Gill IS, Cacciamani GE. Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis. Cancers (Basel). 2021 Aug 30; 13(17). PMID: 34503188; PMCID: PMC8431313.
      Citations: 2     
    84. Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AM. Reply by Authors. J Urol. 2021 11; 206(5):1267. PMID: 34372685.
      Citations:    Fields:    
    85. Galsky MD, Balar AV, Black PC, Campbell MT, Dykstra GS, Grivas P, Gupta S, Hoimes CJ, Lopez LP, Meeks JJ, Plimack ER, Rosenberg JE, Shore N, Steinberg GD, Kamat AM. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. J Immunother Cancer. 2021 07; 9(7). PMID: 34266883; PMCID: PMC8286774.
      Citations: 3     Fields:    Translation:Humans
    86. Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AM. Progression of Disease after Bacillus Calmette-Gu?rin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. J Urol. 2021 11; 206(5):1258-1267. PMID: 34184926.
      Citations: 1     Fields:    Translation:Humans
    87. Westerman ME, Bree KK, Kokorovic A, Frank J, Wang XS, Kamat AM, Dinney CPN, Navai N. What Women Want: Radical Cystectomy and Perioperative Sexual Function Educational Needs. Urology. 2021 11; 157:181-187. PMID: 34186127.
      Citations: 1     Fields:    Translation:Humans
    88. Williams SB, Gavaghan MB, Fernandez A, Daneshmand S, Kamat AM. Macro and microeconomics of blue light cystoscopy with CYSVIEW? in non-muscle invasive bladder cancer. Urol Oncol. 2022 01; 40(1):10.e7-10.e12. PMID: 34158205.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    89. Giannarini G, Agarwal N, Apolo AB, Briganti A, Grivas P, Gupta S, Kamat AM, Montorsi F, Necchi A, Roupr?t M. Urologists, You'll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2022 06; 5(3):268-272. PMID: 34147473.
      Citations:    Fields:    Translation:Humans
    90. Lobo N, Brooks NA, Zlotta AR, Cirillo JD, Boorjian S, Black PC, Meeks JJ, Bivalacqua TJ, Gontero P, Steinberg GD, McConkey D, Babjuk M, Alfred Witjes J, Kamat AM. 100 years of Bacillus Calmette-Gu?rin immunotherapy: from cattle to COVID-19. Nat Rev Urol. 2021 10; 18(10):611-622. PMID: 34131332; PMCID: PMC8204595.
      Citations: 12     Fields:    Translation:HumansAnimals
    91. Bree KK, Hensley PJ, Brooks N, Matulay J, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center. World J Urol. 2021 Nov; 39(11):4143-4149. PMID: 34117914.
      Citations: 1     Fields:    Translation:Humans
    92. Steinberg RL, Packiam VT, Thomas LJ, Brooks N, Vitale A, Mott SL, Crump T, Wang J, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA. Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. Urol Oncol. 2022 01; 40(1):9.e1-9.e7. PMID: 34092482.
      Citations: 1     Fields:    Translation:Humans
    93. Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Krieger LEM, Singer EA, Bajorin DF, Grivas P, Seo HK, Nishiyama H, Konety BR, Li H, Nam K, Kapadia E, Frenkl T, de Wit R, Roumigui? M. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021 07; 22(7):919-930. PMID: 34051177.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    94. Kokorovic A, Westerman ME, Krause K, Hernandez M, Brooks N, Dinney CPN, Kamat AM, Navai N. Revisiting an Old Conundrum: A Systematic Review and Meta-Analysis of Intravesical Therapy for Treatment of Urothelial Carcinoma of the Prostate. Bladder Cancer. 2021 May 25; 7(2):243-252. PMID: 34195319; PMCID: PMC8204151.
      Citations:    
    95. Chan VW, Tan WS, Leow JJ, Tan WP, Ong WLK, Chiu PK, Gurung P, Pirola GM, Orecchia L, Liew MPC, Lee HY, Wang Y, Chen IA, Wroclawski ML, Mayor N, Sathianathen NJ, Braga I, Liu Z, Moon D, Tikkinen K, Kamat A, Meng M, Ficarra V, Giannarini G, Teoh JY, Castellani D. Delayed surgery for localised and metastatic renal cell carcinoma: a systematic review and meta-analysis for the COVID-19 pandemic. World J Urol. 2021 Dec; 39(12):4295-4303. PMID: 34031748; PMCID: PMC8143063.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    96. van der Kwast T, Van Rhijn B, Kamat A, Cheng L. Reply to Rodolfo Montironi, Marina Scarpelli, Alessia Cimadamore, and Gregor Mikuz's Letter to the Editor re: Theo van der Kwast, Fredrik Liedberg, Peter C. Black, et al. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.03.017. Focus on Our Personal Recollections and Observations. Eur Urol Focus. 2022 05; 8(3):885-886. PMID: 33992577.
      Citations:    Fields:    
    97. Green EA, Li R, Albiges L, Choueiri TK, Freedman M, Pal S, Kamat AM, Dyrskj?t L. Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. Eur Urol Oncol. 2021 12; 4(6):893-903. PMID: 33975782.
      Citations: 4     Fields:    Translation:Humans
    98. Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Navai N, Grossman HB, Dinney CP, Kamat AM, Nogueras Gonz?lez GM. Time interval from transurethral resection of bladder tumour to bacille Calmette-Gu?rin induction does not impact therapeutic response. BJU Int. 2021 11; 128(5):634-641. PMID: 33783950.
      Citations: 1     Fields:    Translation:Humans
    99. Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Nogueras-Gonzalez GM, Nagaraju S, Navai N, Grossman HB, Dinney CP, Kamat AM. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Gu?rin Therapy Outcomes. Eur Urol Oncol. 2022 06; 5(3):347-356. PMID: 33935020; PMCID: PMC8553807.
      Citations:    Fields:    Translation:Humans
    100. Bree KK, Hensley PJ, Westerman ME, Kokorovic A, Nogueras-Gonzalez GM, Dinney CP, Kamat AM, Navai N. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. J Urol. 2021 Sep; 206(3):577-585. PMID: 33872050.
      Citations: 1     Fields:    Translation:Humans
    101. Bree KK, Brooks NA, Kamat AM. Current Therapy and Emerging Intravesical Agents to Treat Non-Muscle Invasive Bladder Cancer. Hematol Oncol Clin North Am. 2021 06; 35(3):513-529. PMID: 33958148.
      Citations: 1     Fields:    Translation:Humans
    102. Kukreja JB, Li R, Narayan VM, Lim A, Seif M, Wang X, Kamat A, Dinney C, Navai N. Oncologic Equipoise Between Robotic and Open Radical Cystectomy. J Endourol. 2021 08; 35(8):1168-1176. PMID: 33619985.
      Citations:    Fields:    Translation:Humans
    103. van der Kwast T, Black PC, Kamat A, van Rhijn BWG, Berman DM, Samaratunga H, Varma M, Cheng L, Liedberg F, Algaba F, Hartmann A, Lopez-Beltran A. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. Eur Urol Focus. 2022 03; 8(2):438-446. PMID: 33771477.
      Citations: 3     Fields:    Translation:Humans
    104. Matulay JT, Li R, Hensley PJ, Brooks NA, Narayan VM, Grossman HB, Navai N, Dinney CPN, Kamat AM. Reply by Authors. J Urol. 2021 06; 205(6):1620-1621. PMID: 33734859.
      Citations:    Fields:    
    105. Hugar LA, Gilbert SM, Sexton WJ, Kamat AM, Li R. Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer. Curr Opin Urol. 2021 03 01; 31(2):160-169. PMID: 33394766.
      Citations:    Fields:    Translation:Humans
    106. Feldman AS, Kulkarni GS, Bivalacqua TJ, Black PC, Delacroix S, Lerner SP, Kamat AM, Kassouf W. Surgical challenges and considerations in Tri-modal therapy for muscle invasive bladder cancer. Urol Oncol. 2022 10; 40(10):442-450. PMID: 33642229.
      Citations: 1     Fields:    
    107. Jazzar U, Shan Y, Wallis CJD, Freedland SJ, Kamat AM, Tyler DS, Baillargeon J, Kuo YF, Klaassen Z, Williams SB, Bergerot CD. Use of psychotropic drugs among older patients with bladder cancer in the United States. Psychooncology. 2021 06; 30(6):832-843. PMID: 33507622.
      Citations:    Fields:    Translation:Humans
    108. Bree KK, Hensley PJ, Brooks NA, Matulay J, Li R, Nogueras Gonzalez GM, Navai N, Grossman HB, Matin SF, Dinney CPN, Kamat AM. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. BJU Int. 2021 11; 128(5):568-574. PMID: 33484074.
      Citations:    Fields:    Translation:Humans
    109. Vlahou A, Apweiler R, Beige J, Benigni A, Bischoff R, Black PC, Chrousos GP, Delles C, Evenepoel P, Fridolin I, Glorieux G, van Gool AJ, Ioannidis JPA, Jankowski J, Jankowski V, Jeronimo C, Kamat AM, Masereeuw R, Mischak H, Remuzzi G, Rossing P, Spasovski G, Staessen JA, Stamatialis D, Stenvinkel P, Williams SB, Zoccali C, Vanholder R, Hallinan D, Argiles A, Boehm F, C?raline J, Heidegger I, Mayer G, Ortiz A, Schanstra JP, Schmitz-Dr?ger BJ, Wanner C, Zannad F. Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics? Hypertension. 2021 04; 77(4):1029-1035. PMID: 33583200; PMCID: PMC7968961.
      Citations: 3     Fields:    Translation:Humans
    110. Matulay JT, Li R, Hensley PJ, Brooks NA, Narayan VM, Grossman HB, Navai N, Dinney CPN, Kamat AM. Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Gu?rin: Implications for Clinical Trial Design. J Urol. 2021 06; 205(6):1612-1621. PMID: 33502236.
      Citations: 2     Fields:    Translation:Humans
    111. Li R, Lerner SP, Kamat AM. The Who, What, When, Where, and Why of Bacillus Calmette-Gu?rin-unresponsive Bladder Cancer. Eur Urol. 2021 04; 79(4):437-439. PMID: 33454163.
      Citations:    Fields:    Translation:Humans
    112. Brooks NA, Puri A, Garg S, Nag S, Corbo J, Turabi AE, Kaka N, Zemmel RW, Hegarty PK, Kamat AM. The association of Coronavirus Disease-19 mortality and prior bacille Calmette-Guerin vaccination: a robust ecological analysis using unsupervised machine learning. Sci Rep. 2021 01 12; 11(1):774. PMID: 33436946; PMCID: PMC7804196.
      Citations: 12     Fields:    Translation:HumansPHPublic Health
    113. Yang M, Georgieva MV, Bocharova I, Vembusubramanian M, Qian K, Guo A, Kamat AM. The Impact of Progression on Healthcare Resource Utilization and Costs Among Patients with High-Grade Non-Muscle Invasive Bladder Cancer After Bacillus Calmette-Gu?rin Therapy: A Retrospective SEER-Medicare Analysis. Adv Ther. 2021 03; 38(3):1584-1600. PMID: 33543424.
      Citations:    Fields:    Translation:Humans
    114. Kukreja JB, Seif MA, Mery MW, Incalcaterra JR, Kamat AM, Dinney CP, Shah JB, Feeley TW, Navai N. Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers. Urol Oncol. 2021 04; 39(4):237.e1-237.e5. PMID: 33308972.
      Citations:    Fields:    Translation:Humans
    115. Brooks NA, Kokorovic A, Xiao L, Matulay JT, Li R, Ranasinghe WKB, Nagaraju S, Shen Y, Gao J, Navai N, Dinney CPN, Grossman HB, Kamat AM. The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu?rin. BJU Int. 2021 07; 128(1):65-71. PMID: 33210440.
      Citations: 1     Fields:    Translation:Humans
    116. Polo-Alonso E, Kuk C, Guruli G, Paul AK, Thalmann G, Kamat A, Solsona E, Thalmann G, Urdaneta AI, Zlotta AR, Mir MC. Trimodal therapy in muscle invasive bladder cancer management. Minerva Urol Nefrol. 2020 Dec; 72(6):650-662. PMID: 33263367.
      Citations:    Fields:    Translation:Humans
    117. Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117. PMID: 33253641; PMCID: PMC7988888.
      Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
    118. Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851. PMID: 33046869.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    119. Bagheri I, Shan Y, Klaassen Z, Kamat AM, Konety B, Mehta HB, Baillargeon JG, Srinivas S, Tyler DS, Swanson TA, Kaul S, Hollenbeck BK, Williams SB. Comparing Costs of Radical Versus Partial Cystectomy for Patients Diagnosed With Localized Muscle-Invasive Bladder Cancer: Understanding the Value of Surgical Care. Urology. 2021 01; 147:127-134. PMID: 32980405.
      Citations:    Fields:    Translation:Humans
    120. Teoh JY, Huang J, Ko WY, Lok V, Choi P, Ng CF, Sengupta S, Mostafid H, Kamat AM, Black PC, Shariat S, Babjuk M, Wong MC. Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. Eur Urol. 2020 12; 78(6):893-906. PMID: 32972792.
      Citations: 29     Fields:    Translation:Humans
    121. Koti M, Ingersoll MA, Gupta S, Lam CM, Li X, Kamat AM, Black PC, Siemens DR. Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment. Eur Urol Oncol. 2020 10; 3(5):622-630. PMID: 32967818.
      Citations: 11     Fields:    Translation:HumansAnimals
    122. Gupta S, Kamat AM. Author Correction: NICE's rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good? Nat Rev Urol. 2020 Sep; 17(9):540. PMID: 32719534; PMCID: PMC7608133.
      Citations:    Fields:    
    123. Gupta S, Kamat AM. NICE's rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good? Nat Rev Urol. 2020 09; 17(9):491-492. PMID: 32632305; PMCID: PMC7338128.
      Citations: 3     Fields:    Translation:Humans
    124. Li R, Gilbert SM, Kamat AM. Unraveling the Mechanism of the Antitumor Activity of Bacillus Calmette-Gu?rin. Eur Urol. 2021 07; 80(1):1-3. PMID: 32861573; PMCID: PMC7448869.
      Citations: 3     Fields:    Translation:Humans
    125. Westerman ME, Kokorovic A, Wang XS, Lim A, Garcia-Gonzalez A, Seif M, Wang R, Kamat AM, Dinney CPN, Navai N. Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis. J Sex Med. 2020 10; 17(10):1995-2004. PMID: 32713807.
      Citations:    Fields:    Translation:Humans
    126. Mostafid H, Kamat AM, Daneshmand S, Palou J, Taylor JA, McKiernan J, Catto J, Babjuk M, Soloway M. Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. Eur Urol Oncol. 2021 02; 4(1):12-19. PMID: 32684515.
      Citations: 5     Fields:    Translation:Humans
    127. Brooks NA, Kokorovic A, McGrath JS, Kassouf W, Collins JW, Black PC, Douglas J, Djaladat H, Daneshmand S, Catto JWF, Kamat AM, Williams SB. Critical analysis of quality of life and cost-effectiveness of enhanced recovery after surgery (ERAS) for patient's undergoing urologic oncology surgery: a systematic review. World J Urol. 2022 Jun; 40(6):1325-1342. PMID: 32648071.
      Citations: 8     Fields:    Translation:Humans
    128. Hwang MJ, Kamat AM, Dinney CP, Czerniak B, Guo CC. Bladder Cancer Involving Smooth Muscle of Indeterminate Type or Muscularis Mucosae in Transurethral Biopsy Specimens. Am J Clin Pathol. 2020 07 07; 154(2):208-214. PMID: 32253420; PMCID: PMC7768762.
      Citations:    Fields:    Translation:Humans
    129. Williams SB, Cumberbatch MGK, Kamat AM, Jubber I, Kerr PS, McGrath JS, Djaladat H, Collins JW, Packiam VT, Steinberg GD, Lee E, Kassouf W, Black PC, Cerantola Y, Catto JWF, Daneshmand S. Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. Eur Urol. 2020 11; 78(5):719-730. PMID: 32624275.
      Citations: 15     Fields:    Translation:Humans
    130. Golla V, Shan Y, Mehta HB, Klaassen Z, Tyler DS, Baillargeon J, Kamat AM, Freedland SJ, Gore JL, Chamie K, Kuo YF, Williams SB. Impact of Diagnosing Urologists and Hospitals on the Use of Radical Cystectomy. Eur Urol Open Sci. 2020 Jul; 19:27-36. PMID: 34337452; PMCID: PMC8317809.
      Citations:    
    131. Brooks NA, Narayan V, Hegarty PK, Zafirakis H, Han XY, Kamat AM. The role of the urologist, BCG vaccine administration, and SARS-CoV-2: An overview. BJUI Compass. 2020 Jul; 1(3):87-92. PMID: 32835353; PMCID: PMC7361196.
      Citations: 4     
    132. Brooks N, Nagaraju S, Matulay J, Han XY, Kamat AM. Bacillus Calmette-Gu?rin Retains Clinically Relevant Viability for up to 72 Hours After Reconstitution: Potential Implications for Clinical Practice in Times of Shortage. Eur Urol Oncol. 2021 10; 4(5):826-828. PMID: 32475716.
      Citations: 1     Fields:    Translation:Humans
    133. Yang G, Bondaruk J, Cogdell D, Wang Z, Lee S, Lee JG, Zhang S, Choi W, Wang Y, Liang Y, Wang G, Wang Y, Yao H, Dadhania V, Gao J, Logothetis C, Siefker-Radtke A, Kamat A, Dinney C, Theodorescu D, Kimmel M, Wei P, Guo CC, Weinstein JN, McConkey DJ, Czerniak B. Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. iScience. 2020 Jun 26; 23(6):101201. PMID: 32521509; PMCID: PMC7286965.
      Citations: 5     
    134. Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, Gillessen S, James N, Maclennan S, Powles T, Ribal MJ, Shariat SF, Van Der Kwast T, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Chiti A, Choudhury A, Crabb S, De Blok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Geavlete B, Gontero P, Hafeez S, Hansel DE, Hayne D, Henry AM, Herr H, Hoskin P, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Lara PC, Leliveld A, Meijer R, Moschini M, Mostafid H, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Osanto S, Oyen WJG, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Salembier C, Salminen A, Sengupta S, Smeenk RJ, Smits A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Willemse PM, Williams A, Horwich A, De Santis M, Palou J, Xylinas E, Cathomas R, Comp?rat E, Culine S, De Bari B, Dominguez-Escrig JL, Gakis G, Grubm?ller B, Hartmann A, Hernandez V, Herrmann K, Huguet J, Ladoire S, Linares-Espin?s E, L?gager V, Lorch A, Loriot Y, Mir MC, M?ller AC, M?ller CR, Oldenburg J, Pacheco-Figueiredo L, Roupr?t M, Rouvi?re O, Sargos P, Sherif A, Stenzl A, Valdagni R, Veskim?e E, Zigeuner R. Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]. Eur Urol. 2020 Jul; 78(1):e48-e50. PMID: 32446863.
      Citations:    Fields:    
    135. Matulay JT, Tabayoyong W, Duplisea JJ, Chang C, Daneshmand S, Gore JL, Holzbeierlein JM, Karsh LI, Kim SP, Konety BR, Li R, McKiernan JM, Messing EM, Steinberg GD, Williams SB, Kamat AM. Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. Urol Oncol. 2020 10; 38(10):796.e1-796.e6. PMID: 32430255.
      Citations: 2     Fields:    Translation:Humans
    136. O'Connor E, Teh J, Kamat AM, Lawrentschuk N. Bacillus Calmette Gu?rin (BCG) vaccination use in the fight against COVID-19 - what's old is new again? Future Oncol. 2020 Jul; 16(19):1323-1325. PMID: 32406253; PMCID: PMC7222530.
      Citations: 11     Fields:    Translation:HumansCellsPHPublic Health
    137. Norman PH, Calderon TM, Wang Y, Kamat AM. Inclusion of Anesthesiologists and Surgeons While Developing Guidelines for Management of Immune-Related Adverse Events. J Immunother Precis Oncol. 2020 May; 3(2):56-57. PMID: 36751525; PMCID: PMC9179397.
      Citations:    
    138. Wallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, Morgan TM, Mottet N, Bossi A, Powles T, Necchi A, Catto JWF, Klaassen Z, Gillessen S, Roupret M. Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. Eur Urol. 2020 Jul; 78(1):29-42. PMID: 32414626; PMCID: PMC7196384.
      Citations: 52     Fields:    Translation:HumansCellsPHPublic Health
    139. Jazzar U, Shan Y, Klaassen Z, Freedland SJ, Kamat AM, Raji MA, Masel T, Tyler DS, Baillargeon J, Kuo YF, Mehta HB, Bergerot CD, Williams SB. Impact of Alzheimer's disease and related dementia diagnosis following treatment for bladder cancer. J Geriatr Oncol. 2020 09; 11(7):1118-1124. PMID: 32354675.
      Citations:    Fields:    Translation:Humans
    140. Kamat AM. Bladder Cancer Guidelines: Let Not the Cure Be Worse than the Disease. Eur Urol. 2021 01; 79(1):105-106. PMID: 32360051; PMCID: PMC7183970.
      Citations:    Fields:    Translation:Humans
    141. Hegarty PK, Sfakianos JP, Giannarini G, DiNardo AR, Kamat AM. COVID-19 and Bacillus Calmette-Gu?rin: What is the Link? Eur Urol Oncol. 2020 06; 3(3):259-261. PMID: 32327396; PMCID: PMC7152883.
      Citations: 32     Fields:    Translation:HumansCellsPHPublic Health
    142. Kamat AM, Lerner SP, O'Donnell M, Georgieva MV, Yang M, Inman BA, Kassouf W, Boorjian SA, Tyson MD, Kulkarni GS, Chang SS, Konety BR, Svatek RS, Balar A, Witjes JA. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2020 06; 3(3):318-340. PMID: 32201133.
      Citations: 9     Fields:    Translation:Humans
    143. Mostafid H, Babjuk M, Bochner B, Lerner SP, Witjes F, Palou J, Roupret M, Shariat S, Gontero P, van Rhijn B, Zigeuner R, Sylvester R, Comperat E, Burger M, Malavaud B, Soloway M, Williams S, Black P, Daneshmand S, Steinberg G, Brausi M, Catto J, Kamat AM. Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. Eur Urol. 2020 06; 77(6):669-670. PMID: 32192815.
      Citations: 9     Fields:    Translation:Humans
    144. Necchi A, Gallina A, Kamat AM, Spiess PE, Grivas P, Gibb EA, Briganti A, Montorsi F, Dyrskj?t L, Roupret M. Converging Roads to Early Bladder Cancer. Eur Urol. 2020 08; 78(2):127-130. PMID: 32197887.
      Citations:    Fields:    Translation:Humans
    145. Kamat AM, Shore N, Hahn N, Alanee S, Nishiyama H, Shariat S, Nam K, Kapadia E, Frenkl T, Steinberg G. KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. Future Oncol. 2020 Apr; 16(10):507-516. PMID: 32162533.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    146. Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, Poch MA, Sexton WJ, Black PC, McKiernan JM, Steinberg GD, Kamat AM, Gilbert SM. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Gu?rin. Eur Urol. 2020 09; 78(3):387-399. PMID: 32143924; PMCID: PMC7771323.
      Citations: 7     Fields:    Translation:Humans
    147. Elsherif SB, Kuchana V, Aslam R, Kamat A, Bhosale PR, Klekers AR. Locally advanced prostate cancer imaging findings and implications for treatment from the surgical perspective. Abdom Radiol (NY). 2020 03; 45(3):865-877. PMID: 31724081.
      Citations: 1     Fields:    Translation:Humans
    148. Matulay JT, Soloway M, Witjes JA, Buckley R, Persad R, Lamm DL, Boehle A, Kamat AM, Palou J, Colombel M, Brausi M. Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group?(IBCG). BJU Int. 2020 04; 125(4):497-505. PMID: 31950596.
      Citations: 10     Fields:    Translation:Humans
    149. Li R, Kamat AM. Predictors of Response to Intravesical Therapy. Urol Clin North Am. 2020 Feb; 47(1):23-33. PMID: 31757297.
      Citations: 3     Fields:    Translation:Humans
    150. Narayan VM, Seif MA, Lim AH, Li R, Matulay JT, Kukreja JB, Qiao W, Hwang H, Shah JB, Pisters L, Kamat AM, Dinney C, Navai N. Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes. Urol Oncol. 2020 04; 38(4):247-254. PMID: 31953001.
      Citations: 1     Fields:    Translation:Humans
    151. Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T, Rao MY, Daniels MJ, Wang J, Nagaraju S, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer. J Urol. 2020 05; 203(5):902-909. PMID: 31821066.
      Citations: 19     Fields:    Translation:Humans
    152. Apolo AB, Milowsky MI, Kim L, Inman BA, Kamat AM, Steinberg G, Bagheri M, Krishnasamy VP, Marko J, Dinney CP, Bangs R, Sweis RF, Maher VE, Ibrahim A, Liu K, Werntz R, Cross F, Beaver JA, Singh H, Pazdur R, Blumenthal GM, Lerner SP, Bajorin DF, Rosenberg JE, Agrawal S. Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. JAMA Oncol. 2019 12 01; 5(12):1790-1798. PMID: 31670753; PMCID: PMC8211913.
      Citations: 3     Fields:    Translation:Humans
    153. Williams SB, Black PC, Seiler R, Nawroth R, Kamat AM, Goebell PJ, Dyrskj?t L, Schmitz-Dr?ger B, Todenh?fer T. Re: Aur?lie Kamoun, Aur?lien de Reyni?s, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol 2020;77:420-33: A Statement from the International Bladder Cancer Network. Eur Urol. 2020 04; 77(4):e105-e106. PMID: 31787429.
      Citations: 2     Fields:    Translation:Humans
    154. Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, Gillessen S, James N, Maclennan S, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Chiti A, Choudhury A, Crabb S, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Geavlete B, Gontero P, Hafeez S, Hansel DE, Hayne D, Henry AM, Herr H, Hoskin P, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Lara PC, Leliveld A, Meijer R, Moschini M, Mostafid H, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Osanto S, J G Oyen W, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Salembier C, Salminen A, Sengupta S, Smeenk RJ, Smits A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Horwich A, De Santis M, Palou J, Xylinas E, Cathomas R, Comp?rat E, Culine S, De Bari B, Dominguez-Escrig JL, Gakis G, Grubm?ller B, Hartmann A, Hernandez V, Herrmann K, Huguet J, Ladoire S, Linares-Espin?s E, L?gager V, Lorch A, Loriot Y, Mir MC, M?ller AC, M?ller CR, Oldenburg J, Pacheco-Figueiredo L, Roupr?t M, Rouvi?re O, Sargos P, Sherif A, Stenzl A, Valdagni R, Veskim?e E, Zigeuner R. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort?: Under the Auspices of the EAU-ESMO Guidelines Committees. Eur Urol. 2020 02; 77(2):223-250. PMID: 31753752.
      Citations: 36     Fields:    Translation:Humans
    155. Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, Brant A, Mikkilineni N, McConkey DJ, Kamat AM, Svatek RS, Porten SP, Meeks JJ, Lerner SP, Dinney CP, Black PC, McKiernan JM, Anderson C, Drake CG, Bivalacqua TJ. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clin Cancer Res. 2020 02 15; 26(4):882-891. PMID: 31712383.
      Citations: 29     Fields:    Translation:HumansCells
    156. Horwich A, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, Gillessen S, James N, Maclennan S, Powles T, Ribal MJ, Shariat SF, Van Der Kwast T, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Chiti A, Choudhury A, Crabb S, DeBlok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Geavlete B, Gontero P, Hafeez S, Hansel DE, Hayne D, Henry AM, Herr H, Hoskin P, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Lara PC, Leliveld A, Meijer R, Moschini M, Mostafid H, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Osanto S, Oyen WJG, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Salembier C, Salminen A, Sengupta S, Smeenk RJ, Smits A, Thalmann GN, Tombal B, Turkbey B, Vahr Lauridsen S, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Vilaseca A, Vives Rivera FA, Wiegel T, Wiklund P, Williams A, Witjes JA, De Santis M, Palou J, Xylinas E, Cathomas R, Comp?rat E, Culine S, De Bari B, Dominguez-Escrig JL, Gakis G, Grubm?ller B, Hartmann A, Hernandez V, Herrmann K, Huguet J, Ladoire S, Linares-Espin?s E, L?gager V, Lorch A, Loriot Y, Carmen Mir M, M?ller AC, M?ller CR, Oldenburg J, Pacheco-Figueiredo L, Roupr?t M, Rouvi?re O, Sargos P, Sherif A, Stenzl A, Valdagni R, Veskim?e E, Zigeuner R. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees?. Ann Oncol. 2019 11 01; 30(11):1697-1727. PMID: 31740927; PMCID: PMC7360152.
      Citations: 16     Fields:    Translation:Humans
    157. Soloway M, Matulay JT, Kamat AM. A Case for Risk-adapted Management of Low-grade Bladder Tumors. Eur Urol Oncol. 2020 02; 3(1):128-129. PMID: 31645295.
      Citations: 1     Fields:    Translation:Humans
    158. Espinos EL, Bruins HM, Yuan Y, Sylvester R, Kamat AM, Shariat SF, Witjes JA, Veskim?e E, Comp?rat EM. What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review. Eur Urol Oncol. 2019 Nov; 2(6):625-642. PMID: 31601522.
      Citations: 23     Fields:    Translation:Humans
    159. Oddens JR, Vernooij RWM, Li R, Kamat A, Dinney CP, Savic S, Thalmann GN, Bubendorf L, Sylvester RJ, de Reijke TM, Liem EIML, Mengual L, Alcaraz A, Izquierdo L. The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Gu?rin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. J Urol. 2020 02; 203(2):283-291. PMID: 31549936.
      Citations:    Fields:    Translation:Humans
    160. Lobo N, Shariat SF, Guo CC, Kassouf W, Choudhury A, Gao J, Williams SB, Galsky MD, Taylor JA, Kamat AM, Fernandez MI, Roupret M. What Is the Significance of Variant Histology in Urothelial Carcinoma? Eur Urol Focus. 2020 07 15; 6(4):653-663. PMID: 31530497.
      Citations: 25     Fields:    Translation:Humans
    161. Shariat SF, Black P, Kamat AM, Stabile A, Cathelineau X, Kassouf W, Bochner BH, Boorjian SA, Catto JW, Sanchez-Salas R, Moschini M, Xylinas E, Roupret M. Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. Eur Urol. 2020 01; 77(1):1-2. PMID: 31506227.
      Citations:    Fields:    Translation:Humans
    162. Burger M, Kamat AM, McConkey D. Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer? Eur Urol Oncol. 2021 06; 4(3):510-514. PMID: 31395481.
      Citations: 2     Fields:    Translation:Humans
    163. Williams SB, Shan Y, Ray-Zack MD, Hudgins HK, Jazzar U, Tyler DS, Freedland SJ, Swanson TA, Baillargeon JG, Hu JC, Kaul S, Kamat AM, Gore JL, Mehta HB. Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer. JAMA Surg. 2019 08 01; 154(8):e191629. PMID: 31166593; PMCID: PMC6551585.
      Citations: 13     Fields:    Translation:Humans
    164. Seiler R, Black PC, Williams SB, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dr?ger BJ. Editorial: Bladder cancer within the focus of basic and clinical research. Sixth IBCN Seminars Series. Urol Oncol. 2019 11; 37(11):815-817. PMID: 31377169.
      Citations:    Fields:    Translation:HumansAnimals
    165. Kamat AM, Gontero P, Palou J. How Should I Manage a Patient with Tumor Recurrence Despite Adequate Bacille Calmette-Gu?rin? Eur Urol Oncol. 2020 04; 3(2):252-257. PMID: 31307960.
      Citations:    Fields:    Translation:Humans
    166. Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat AM, Konety B, McKiernan J, O'Donnell M, Patel S, Pohar K, Resnick M, Sankin A, Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S, Malmstr?m PU. Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018. Nat Rev Urol. 2019 06; 16(6):377-386. PMID: 31019310; PMCID: PMC7136177.
      Citations: 11     Fields:    Translation:Humans
    167. Guo CC, Majewski T, Zhang L, Yao H, Bondaruk J, Wang Y, Zhang S, Wang Z, Lee JG, Lee S, Cogdell D, Zhang M, Wei P, Grossman HB, Kamat A, Duplisea JJ, Ferguson JE, Huang H, Dadhania V, Gao J, Dinney C, Weinstein JN, Baggerly K, McConkey D, Czerniak B. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Rep. 2019 05 07; 27(6):1781-1793.e4. PMID: 31067463; PMCID: PMC6546434.
      Citations: 31     Fields:    Translation:HumansCells
    168. Flannery K, Boyd M, Black-Shinn J, Robert N, Kamat AM. Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study. Future Oncol. 2019 Apr; 15(12):1323-1334. PMID: 30942088.
      Citations: 8     Fields:    Translation:Humans
    169. Li R, Kukreja JEB, Seif MA, Petros FG, Campbell MT, Nguyen JV, Kamat AM, Pisters LL, Dinney CP, Navai N, Gonz?lez GMN. The role of metastatic burden in cytoreductive/consolidative radical cystectomy. World J Urol. 2019 Dec; 37(12):2691-2698. PMID: 30864005.
      Citations: 4     Fields:    Translation:Humans
    170. Boormans JL, Zwarthoff EC, Black PC, Goebell PJ, Kamat AM, Seiler R, Williams SB, Nawroth R, Schmitz-Dr?ger BJ. New horizons in bladder cancer research. Urol Oncol. 2020 12; 38(12):867-885. PMID: 30852032.
      Citations: 5     Fields:    Translation:Humans
    171. Matulay JT, Narayan VM, Kamat AM. Clinical and Genomic Considerations for Variant Histology in Bladder Cancer. Curr Oncol Rep. 2019 02 26; 21(3):23. PMID: 30806832.
      Citations: 7     Fields:    Translation:Humans
    172. Williams SB, Kamat AM, Mehta HB. Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer-Reply. JAMA Surg. 2019 02 01; 154(2):186. PMID: 30476959.
      Citations:    Fields:    Translation:Humans
    173. Kamat AM, Shariat SF, Plimack ER, Pignot G, Loriot Y. Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies. Eur Urol Oncol. 2019 07; 2(4):355-364. PMID: 31277773.
      Citations: 9     Fields:    Translation:Humans
    174. Matulay JT, Woldu SL, Lim A, Narayan VM, Li G, Kamat AM, Anderson CB. The impact of squamous histology on survival in patients with muscle-invasive bladder cancer. Urol Oncol. 2019 06; 37(6):353.e17-353.e24. PMID: 30704959.
      Citations: 6     Fields:    Translation:Humans
    175. Black PC, Goebell PJ, Kamat AM, Seiler R, Williams SB, Nawroth R, Schmitz-Dr?ger BJ. Editorial: Basic research in bladder cancer - refining the tools. 3rd IBCN seminars series1. Urol Oncol. 2020 12; 38(12):855-857. PMID: 30683454.
      Citations:    Fields:    Translation:HumansAnimalsCells
    176. Peyton CC, Chipollini J, Azizi M, Kamat AM, Gilbert SM, Spiess PE. Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what. World J Urol. 2019 Oct; 37(10):2017-2029. PMID: 30535583.
      Citations: 16     Fields:    Translation:Humans
    177. Ray-Zack MD, Shan Y, Mehta HB, Yu X, Kamat AM, Williams SB. Hospital length of stay following radical cystectomy for muscle-invasive bladder cancer: Development and validation of a population-based prediction model. Urol Oncol. 2019 11; 37(11):837-843. PMID: 30446462; PMCID: PMC7682754.
      Citations:    Fields:    Translation:Humans
    178. Kamat AM, Gontero P. Editorial comment. Curr Opin Urol. 2018 11; 28(6):555-556. PMID: 30256260.
      Citations:    Fields:    Translation:Humans
    179. Tabayoyong W, Kamat AM. Current Use and Promise of Urinary Markers for Urothelial Cancer. Curr Urol Rep. 2018 Oct 17; 19(12):96. PMID: 30328534.
      Citations: 7     Fields:    Translation:Humans
    180. Li R, Tabayoyong WB, Guo CC, Navai N, Grossman HB, Dinney CP, Kamat AM, Gonz?lez GMN. Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease. Eur Urol. 2019 01; 75(1):8-10. PMID: 30301695.
      Citations: 6     Fields:    Translation:Humans
    181. Williams SB, Shan Y, Jazzar U, Mehta HB, Baillargeon JG, Huo J, Senagore AJ, Orihuela E, Tyler DS, Swanson TA, Kamat AM. Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer. JAMA Surg. 2018 10 01; 153(10):881-889. PMID: 29955780; PMCID: PMC6584312.
      Citations: 28     Fields:    Translation:Humans
    182. Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, Kiemeney L, Lotan Y, Pang K, Silverman DT, Znaor A, Catto JWF. Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. Eur Urol. 2018 12; 74(6):784-795. PMID: 30268659.
      Citations: 162     Fields:    Translation:HumansPHPublic Health
    183. Li R, Metcalfe MJ, Tabayoyong WB, Guo CC, Navai N, Grossman HB, Dinney CP, Kamat AM, Nogueras Gonz?lez GM. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. Eur Urol Oncol. 2019 05; 2(3):286-293. PMID: 31200843.
      Citations: 3     Fields:    Translation:Humans
    184. Tabayoyong WB, Kamat AM, O'Donnell MA, McKiernan JM, Ray-Zack MD, Palou J, Brausi M, Black PC, Williams SB. Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer. Eur Urol Focus. 2018 07; 4(4):512-521. PMID: 30190111; PMCID: PMC7810510.
      Citations: 3     Fields:    Translation:Humans
    185. Huo J, Ray-Zack MD, Shan Y, Chamie K, Boorjian SA, Kerr P, Jana B, Freedland SJ, Kamat AM, Mehta HB, Williams SB. Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer. Eur Urol Oncol. 2019 09; 2(5):497-504. PMID: 31411998; PMCID: PMC8362849.
      Citations: 5     Fields:    Translation:Humans
    186. Williams SB, Hudgins HK, Ray-Zack MD, Chamie K, Smaldone MC, Boorjian SA, Daneshmand S, Black PC, Kamat AM, Goebell PJ, Seiler R, Schmitz-Drager B, Nawroth R, Baillargeon J, Klaassen Z, Kulkarni GS, Kim SP, Lee EK, Holzbeierlein JM, Hollenbeck BK, Gore JL. Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. Eur Urol Oncol. 2019 03; 2(2):119-125. PMID: 31017086; PMCID: PMC10039463.
      Citations: 3     Fields:    Translation:Humans
    187. Brausi M, Clark PE, Cookson MS, Grossman HB, Khochikar M, Kiemeney LA, Malavaud B, Sanchez-Salas R, Soloway MS, Svatek RS, Vikram R, Vrieling A, Kamat AM, Fern?ndez MI. Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer. World J Urol. 2019 Jan; 37(1):3-13. PMID: 30105454.
      Citations: 21     Fields:    Translation:Humans
    188. Smith AB, Daneshmand S, Patel S, Pohar K, Trabulsi E, Woods M, Downs T, Huang W, Taylor J, Jones J, O'Donnell M, Bivalacqua T, DeCastro J, Steinberg G, Kamat A, Resnick M, Konety B, Schoenberg M, Jones JS, Lotan Y, Flexible Blue Light Study Group Collaborators. Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study. BJU Int. 2019 01; 123(1):35-41. PMID: 29979488.
      Citations: 7     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    189. Black PC, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dr?ger BJ. New Horizons in Bladder Cancer Research: Report of the 15th Meeting of the International Bladder Cancer Network (IBCN) in Lisbon, Portugal, October 21-23, 2017. Bladder Cancer. 2018 Jul 30; 4(3):339-342. PMID: 30112445; PMCID: PMC6087445.
      Citations:    
    190. Matulay JT, Kamat AM. Advances in risk stratification of bladder cancer to guide personalized medicine. F1000Res. 2018; 7. PMID: 30109022; PMCID: PMC6069735.
      Citations: 9     Fields:    Translation:Humans
    191. Kukreja JB, Metcalfe MJ, Qiao W, Kamat AM, Dinney CPN, Navai N. Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort. Eur Urol Focus. 2020 01 15; 6(1):88-94. PMID: 30033071.
      Citations: 7     Fields:    Translation:Humans
    192. Klaassen Z, Kamat AM, Kassouf W, Gontero P, Bellmunt J, van Rhijn BWG, Hartmann A, Catto JWF, Kulkarni GS, Villavicencio H. Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. Eur Urol. 2018 11; 74(5):597-608. PMID: 30017405.
      Citations: 15     Fields:    Translation:Humans
    193. Williams SB, Kamat AM, Chamie K, Wiklund PN, Black PC, Steinberg GD, Boorjian SA, Daneshmand S, Goebell PJ, Pohar KS, Shariat SF, Thalmann GN, Froehner M, Wirth MP. Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. Eur Urol Oncol. 2018 Jun; 1(2):91-100. PMID: 30345422; PMCID: PMC6190914.
      Citations: 10     Fields:    
    194. Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Kamat AM, Roupret M. Role of Checkpoint Inhibition in Localized Bladder Cancer. Eur Urol Oncol. 2018 08; 1(3):190-198. PMID: 31102620.
      Citations: 6     Fields:    Translation:HumansAnimals
    195. Balasubramanian A, Metcalfe MJ, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF. Salvage topical therapy for upper tract urothelial carcinoma. World J Urol. 2018 Dec; 36(12):2027-2034. PMID: 29804202; PMCID: PMC6261784.
      Citations: 1     Fields:    Translation:Humans
    196. Lotan Y, Black PC, Caba L, Chang SS, Cookson MS, Daneshmand S, Kamat AM, McKiernan JM, Pruthi RS, Ritch CR, Steinberg GD, Svatek RS, Zwarthoff EC. Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review. Eur Urol Oncol. 2018 08; 1(3):223-230. PMID: 31102625.
      Citations: 7     Fields:    Translation:Humans
    197. Briganti A, Albiges L, Giannarini G, Kamat AM, Nguyen PL. Welcome to European Urology Oncology: Your New Journal, Where Multiple Disciplines Meet To Improve Care of Patients with Genitourinary Cancers. Eur Urol Oncol. 2018 05; 1(1):1-2. PMID: 31100222.
      Citations:    Fields:    Translation:Humans
    198. Wang G, Xiao L, Zhang M, Kamat AM, Siefker-Radtke A, Dinney CP, Czerniak B, Guo CC. Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol. 2018 09; 79:57-65. PMID: 29763719; PMCID: PMC6133751.
      Citations: 12     Fields:    Translation:Humans
    199. Mmeje CO, Benson CR, Jayaratna IS, Gao J, Siefker-Radtke AO, Kamat AM, Dinney CP, Navai N, Shah JB, Nogueras-Gonz?lez GM. Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy. BJU Int. 2018 07; 122(1):89-98. PMID: 29569824.
      Citations: 9     Fields:    Translation:Humans
    200. Li R, Spiess PE, Kamat AM. Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious? Eur Urol. 2018 10; 74(4):405-408. PMID: 29685644.
      Citations: 5     Fields:    Translation:Humans
    201. Jazzar U, Yong S, Klaassen Z, Huo J, Hughes BD, Esparza E, Mehta HB, Kim SP, Tyler DS, Freedland SJ, Kamat AM, Wolf DV, Williams SB. Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States. Cancer. 2018 08 01; 124(15):3127-3135. PMID: 29660813; PMCID: PMC6097900.
      Citations: 13     Fields:    Translation:Humans
    202. Flannery K, Cao X, He J, Zhong Y, Shah AY, Kamat AM. Survival Rates and Health Care Costs for Patients With Advanced Bladder Cancer Treated and Untreated With Chemotherapy. Clin Genitourin Cancer. 2018 08; 16(4):e909-e917. PMID: 29735397.
      Citations: 6     Fields:    Translation:Humans
    203. Kukreja JB, Shi Q, Chang CM, Seif MA, Sterling BM, Chen TY, Creel KM, Kamat AM, Dinney CP, Navai N, Shah JB, Wang XS. Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy. Surg Innov. 2018 Jun; 25(3):242-250. PMID: 29557251; PMCID: PMC5995564.
      Citations: 7     Fields:    Translation:Humans
    204. Black PC, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dr?ger BJ. Editorial: Managing locally advanced bladder cancer. Third International Bladder Cancer Network seminars series. Urol Oncol. 2018 09; 36(9):403-404. PMID: 29548621.
      Citations:    Fields:    Translation:Humans
    205. Cumberbatch MGK, Foerster B, Catto JWF, Kamat AM, Kassouf W, Jubber I, Shariat SF, Sylvester RJ, Gontero P. Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. Eur Urol. 2018 06; 73(6):925-933. PMID: 29523366.
      Citations: 45     Fields:    Translation:Humans
    206. Zuiverloon TCM, van Kessel KEM, Bivalacqua TJ, Boormans JL, Ecke TH, Grivas PD, Kiltie AE, Necchi A, van Rhijn BW, Roghmann F, Sanchez-Carbayo M, Wezel F, Kamat AM, Liedberg F, Schmitz-Dr?ger BJ. Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network. Urol Oncol. 2018 09; 36(9):423-431. PMID: 29496372.
      Citations: 2     Fields:    Translation:Humans
    207. Tabayoyong W, Li R, Gao J, Kamat A. Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma. Urol Clin North Am. 2018 May; 45(2):155-167. PMID: 29650132.
      Citations: 5     Fields:    Translation:Humans
    208. Guo CC, Al-Ahmadie HA, Flaig TW, Kamat AM. Contribution of bladder cancer pathology assessment in planning clinical trials. Urol Oncol. 2021 10; 39(10):713-719. PMID: 29395955.
      Citations: 3     Fields:    Translation:Humans
    209. Li R, Baack Kukreja JE, Kamat AM. Secondary Tumors After Urinary Diversion. Urol Clin North Am. 2018 Feb; 45(1):91-99. PMID: 29169454.
      Citations: 3     Fields:    Translation:Humans
    210. Daneshmand S, Patel S, Lotan Y, Pohar K, Trabulsi E, Woods M, Downs T, Huang W, Jones J, O'Donnell M, Bivalacqua T, DeCastro J, Steinberg G, Kamat A, Resnick M, Konety B, Schoenberg M, Jones JS, Flexible Blue Light Study Group Collaborators. Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. J Urol. 2018 05; 199(5):1158-1165. PMID: 29203268.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    211. Ferguson JE, Kamat AM. It's all about the perspective: Removing bias when co-managing patients with high-grade T1 bladder cancer and localized prostate cancer-A competing risks analysis. Urol Oncol. 2018 02; 36(2):39-42. PMID: 29158136.
      Citations:    Fields:    Translation:Humans
    212. Hermans TJN, Voskuilen CS, van der Heijden MS, Kassouf W, Seiler R, Kamat AM, Grivas P, Kiltie AE, Black PC, van Rhijn BWG, Schmitz-Dr?ger BJ. Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future. Urol Oncol. 2018 09; 36(9):413-422. PMID: 29128420.
      Citations: 10     Fields:    Translation:Humans
    213. Abufaraj M, Dalbagni G, Daneshmand S, Horenblas S, Kamat AM, Kanzaki R, Zlotta AR, Shariat SF. The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. Eur Urol. 2018 04; 73(4):543-557. PMID: 29122377; PMCID: PMC8177016.
      Citations: 39     Fields:    Translation:Humans
    214. Lee EK, Kamat AM. Should we care more about SPARE? BJU Int. 2017 11; 120(5):605-606. PMID: 29035018.
      Citations:    Fields:    
    215. Kamat AM, Li R, O'Donnell MA, Black PC, Roupret M, Catto JW, Comperat E, Ingersoll MA, Witjes WP, McConkey DJ, Witjes JA. Predicting Response to Intravesical Bacillus Calmette-Gu?rin Immunotherapy: Are We There Yet? A Systematic Review. Eur Urol. 2018 05; 73(5):738-748. PMID: 29055653.
      Citations: 32     Fields:    Translation:Humans
    216. Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA, Abraham P, Rosenberg JE. Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer. 2017 09 28; 5(1):80. PMID: 28962591; PMCID: PMC5622592.
      Citations: 2     Fields:    
    217. Li R, Metcalfe MJ, Ferguson JE, Mokkapati S, Dinney CP, Navai N, McConkey DJ, Sahai SK, Kamat AM, Nogueras Gonz?lez GM. Effects of thiazolidinedione in patients with active bladder cancer. BJU Int. 2018 02; 121(2):244-251. PMID: 28872778; PMCID: PMC5780258.
      Citations: 3     Fields:    Translation:Humans
    218. Williams SB, Kamat AM, Mmeje C, Ye Y, Huang M, Chang DW, Dinney CP, Wu X. Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Gu?rin. Oncotarget. 2017 Oct 24; 8(51):88782-88791. PMID: 29179475; PMCID: PMC5687645.
      Citations: 1     Fields:    
    219. Jinesh GG, Kamat AM. The Blebbishield Emergency Program Overrides Chromosomal Instability and Phagocytosis Checkpoints in Cancer Stem Cells. Cancer Res. 2017 11 15; 77(22):6144-6156. PMID: 28855211.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    220. Jinesh GG, Manyam GC, Mmeje CO, Baggerly KA, Kamat AM. Surface PD-L1,?E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis. Sci Rep. 2017 08 29; 7(1):9602. PMID: 28851898; PMCID: PMC5575243.
      Citations: 28     Fields:    Translation:HumansCells
    221. Williams SB, Huo J, Chu Y, Baillargeon JG, Daskivich T, Kuo YF, Kosarek CD, Kim SP, Orihuela E, Tyler DS, Freedland SJ, Kamat AM. Cancer and All-cause Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy: Development and Validation of a Nomogram for Treatment Decision-making. Urology. 2017 Dec; 110:76-83. PMID: 28847688; PMCID: PMC8336075.
      Citations: 10     Fields:    Translation:Humans
    222. Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN. Intravesical rAd-IFNa/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017 Oct 20; 35(30):3410-3416. PMID: 28834453; PMCID: PMC5648171.
      Citations: 52     Fields:    Translation:HumansCellsCTClinical Trials
    223. Wang G, Huang H, Kamat AM, Siefker-Radtke A, Dinney CP, Troncoso P, Czerniak B, Guo CC. High-grade neuroendocrine carcinoma of the urachus-report of 3 cases. Hum Pathol. 2017 09; 67:126-133. PMID: 28823575.
      Citations: 1     Fields:    Translation:Humans
    224. Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA, Abraham P, Rosenberg JE. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer. 2017 08 15; 5(1):68. PMID: 28807024; PMCID: PMC5557323.
      Citations: 29     Fields:    Translation:Humans
    225. Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM. Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2017 09; 13(9):621-625. PMID: 28796558.
      Citations: 18     Fields:    Translation:Humans
    226. Kamat AM, Lerner S, Black P, Bellmunt J, Dinney C, Hahn NM, O'Donnell M, Quale DZ. Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer. Bladder Cancer. 2017 Jul 27; 3(3):145-146. PMID: 28824940; PMCID: PMC5545902.
      Citations: 3     
    227. Li R, Sylvester R, Dinney CP, Kamat AM. Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. Bladder Cancer. 2017 Jul 27; 3(3):147-148. PMID: 28824941; PMCID: PMC5545908.
      Citations:    
    228. Flaig TW, Kamat AM, Hansel D, Ingersoll MA, Barton Grossman H, Mendelsohn C, DeGraff D, Liao JC, Taylor JA. Proceedings of the 3rd Annual Albert Institute for Bladder Cancer Research Symposium. Bladder Cancer. 2017 Jul 27; 3(3):211-223. PMID: 28824949; PMCID: PMC5545918.
      Citations: 2     
    229. Huo J, Chu Y, Chamie K, Smaldone MC, Boorjian SA, Baillargeon JG, Kuo YF, Kerr P, O'Malley P, Orihuela E, Tyler DS, Freedland SJ, Giordano SH, Vikram R, Kamat AM, Williams SB. Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed With Bladder Cancer. Clin Genitourin Cancer. 2017 Jul 26. PMID: 28826932; PMCID: PMC5878135.
      Citations: 5     Fields:    
    230. Metcalfe M, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. J Endourol. 2017 09; 31(9):946-953. PMID: 28731777; PMCID: PMC5915259.
      Citations: 9     Fields:    Translation:Humans
    231. Metcalfe MJ, Ferguson JE, Li R, Xiao L, Guo CC, Czerniak BA, Siefker-Radtke A, Pretzsch SM, Navai N, McConkey DJ, Kamat AM, Campbell M, Dinney C. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Eur Urol Focus. 2017 12; 3(6):577-583. PMID: 28753816; PMCID: PMC5767145.
      Citations: 3     Fields:    Translation:Humans
    232. Williams SB, Huo J, Dafashy TJ, Ghaffary CK, Baillargeon JG, Morales EE, Kim SP, Kuo YF, Orihuela E, Tyler DS, Freedland SJ, Kamat AM. Survival differences among patients with bladder cancer according to sex: Critical evaluation of radical cystectomy use and delay to treatment. Urol Oncol. 2017 10; 35(10):602.e1-602.e9. PMID: 28647395; PMCID: PMC8364004.
      Citations: 2     Fields:    Translation:Humans
    233. Myers AL, Zhang YP, Kawedia JD, Zhou X, Sobocinski SM, Metcalfe MJ, Kramer MA, Dinney CPN, Kamat AM. Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration. Drugs R D. 2017 Jun; 17(2):297-304. PMID: 28470465; PMCID: PMC5427054.
      Citations: 4     Fields:    
    234. Jinesh GG, Kamat AM. RalBP1 and p19-VHL play an oncogenic role, and p30-VHL plays a tumor suppressor role during the blebbishield emergency program. Cell Death Discov. 2017; 3:17023. PMID: 28580172; PMCID: PMC5447132.
      Citations: 11     
    235. Williams SB, Huo J, Kosarek CD, Chamie K, Rogers SO, Williams MA, Giordano SH, Kim SP, Kamat AM. Population-based assessment of racial/ethnic differences in utilization of radical cystectomy for patients diagnosed with bladder cancer. Cancer Causes Control. 2017 Jul; 28(7):755-766. PMID: 28477210; PMCID: PMC5497706.
      Citations: 6     Fields:    Translation:Humans
    236. Taoka R, Jinesh GG, Xue W, Safe S, Kamat AM. CF3DODA-Me induces apoptosis, degrades Sp1, and blocks the transformation phase of the blebbishield emergency program. Apoptosis. 2017 05; 22(5):719-729. PMID: 28283889.
      Citations: 10     Fields:    Translation:HumansCells
    237. Fox MD, Xiao L, Zhang M, Kamat AM, Siefker-Radtke A, Zhang L, Dinney CP, Czerniak B, Guo CC. Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases. Am J Clin Pathol. 2017 May 01; 147(5):500-506. PMID: 28371875.
      Citations: 18     Fields:    Translation:Humans
    238. Black PC, Goebell PJ, Kamat AM, Pan Q, Sathe A, Schmitz-Draeger B, Nawroth R. CDK4/6 Inhibitors in Cancer Therapy: A?Novel Treatement Strategy for Bladder Cancer. Bladder Cancer. 2017 Apr 27; 3(2):79-88. PMID: 28516152; PMCID: PMC5409046.
      Citations: 10     
    239. Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol. 2017 09; 198(3):552-559. PMID: 28456635; PMCID: PMC5626446.
      Citations: 160     Fields:    Translation:Humans
    240. Baack Kukreja J, Kamat AM. Strategies to minimize readmission rates following major urologic surgery. Ther Adv Urol. 2017 Oct; 9(5):111-119. PMID: 28588648; PMCID: PMC5444623.
      Citations: 1     
    241. Kamat AM. Bladder cancer: 2017 and beyond. Indian J Urol. 2017 Apr-Jun; 33(2):104-105. PMID: 28469296; PMCID: PMC5396396.
      Citations: 3     
    242. Kamat AM, Bagcioglu M, Huri E. What is new in non-muscle-invasive bladder cancer in 2016? Turk J Urol. 2017 Mar; 43(1):9-13. PMID: 28270945; PMCID: PMC5330275.
      Citations: 11     
    243. Kamat AM, Sundi D, Lamm D, Boehle A, Brausi M, Buckley R, Persad R, Soloway M, Witjes JA, Colombel M, Palou J. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat Rev Urol. 2017 Apr; 14(4):244-255. PMID: 28248951.
      Citations: 32     Fields:    Translation:Humans
    244. Li R, Amrhein J, Cohen Z, Champagne M, Kamat AM. Efficacy of Mycobacterium Phlei Cell Wall-Nucleic Acid Complex (MCNA) in?BCG-Unresponsive Patients. Bladder Cancer. 2017 Jan 27; 3(1):65-71. PMID: 28149937; PMCID: PMC5271425.
      Citations: 6     
    245. Kukreja JB, Porten S, Golla V, Ho PL, Noguera-Gonzalez G, Navai N, Kamat AM, Dinney CPN, Shah JB. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Eur Urol Focus. 2018 09; 4(5):720-724. PMID: 28753837.
      Citations: 7     Fields:    Translation:Humans
    246. Qu K, Gu J, Ye Y, Williams SB, Dinney CP, Wu X, Kamat A. High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis. Oncoimmunology. 2017; 6(2):e1265719. PMID: 28344874; PMCID: PMC5353920.
      Citations: 8     Fields:    
    247. Li R, Choi W, Ferguson Rd JE, Metcalfe MJ, Kamat AM. New discoveries in the molecular landscape of bladder cancer. F1000Res. 2016; 5:2875. PMID: 28105319; PMCID: PMC5225406.
      Citations: 2     Fields:    
    248. Williams SB, Willis DL, Slack RS, Dickstein RJ, Parikh S, Chiong E, Siefker-Radtke AO, Guo CC, Czerniak BA, McConkey DJ, Shah JB, Pisters LL, Grossman HB, Dinney CP, Kamat AM, Fern?ndez MI. Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU Int. 2017 05; 119(5):684-691. PMID: 27753185.
      Citations: 10     Fields:    Translation:Humans
    249. Lamm DL, Kamat AM, Keefe S, Taylor JA, Ingersoll MA, Grossman HB. Innovation in Bladder Cancer Immunotherapy. J Immunother. 2016 10; 39(8):291-7. PMID: 27428265.
      Citations: 2     Fields:    Translation:HumansAnimals
    250. Vlahou A, Black PC, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dr?ger BJ. Taking the next step-Advancing bladder cancer management. Urol Oncol. 2016 10; 34(10):435-6. PMID: 27658683.
      Citations: 1     Fields:    Translation:Humans
    251. Jinesh GG, Kamat AM. Blebbishields and mitotic cells exhibit robust macropinocytosis. Biofactors. 2017 Mar; 43(2):181-186. PMID: 27671897.
      Citations: 6     Fields:    Translation:HumansCells
    252. Zuiverloon TC, Zwarthoff EC, Saltzman A, Srivastava A, Hudson MA, Seiler R, Vlahou A, Grossman HB, Schoenberg MP, Sanchez-Carbayo M, van Rhijn BW, Kamat AM, Shariat SF, Kiemeney LA, Schmitz-Dr?ger BJ, Kuckuck EC, Todenh?fer T, Br?nn LA, Goebell PJ, Roupret M. Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines. Urol Oncol. 2016 10; 34(10):437-51. PMID: 27641313.
      Citations: 7     Fields:    Translation:Humans
    253. Oshiro H, Czerniak BA, Sakamaki K, Tsuta K, Bondaruk J, Keyhani A, Dinney CP, Nagai T, Kamat AM. Comparison between whole mount tissue preparations and virtual tissue microarray samples for measuring Ki-67 and apoptosis indices in human bladder cancer: A cross-sectional study. Medicine (Baltimore). 2016 Aug; 95(31):e4500. PMID: 27495099; PMCID: PMC4979853.
      Citations:    Fields:    Translation:Humans
    254. Navai N, Benedict WF, Zhang G, Abraham A, Ainslie N, Shah JB, Grossman HB, Kamat AM, Dinney CP. Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon a2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer. Ann Surg Oncol. 2016 11; 23(12):4110-4114. PMID: 27387678; PMCID: PMC5459317.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    255. Kassouf W, Traboulsi SL, Witjes JA, van Rhijn BW, Grossman HB, Kiemeney LA, Goebell PJ, Kamat AM, Schmitz-Dr?ger B, Palou J. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations. Urol Oncol. 2016 10; 34(10):460-8. PMID: 27368880.
      Citations: 21     Fields:    Translation:Humans
    256. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Choi W, Guo CC, Lotan Y, Kassouf W, Malmstr?m PU. Bladder cancer. Lancet. 2016 12 03; 388(10061):2796-2810. PMID: 27345655.
      Citations: 407     Fields:    Translation:Humans
    257. Williams SB, Huo J, Chamie K, Hu JC, Giordano SH, Hoffman KE, Dinney CPN, Kamat AM, Shih YT. Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer. Eur Urol Focus. 2017 04; 3(2-3):258-264. PMID: 28753760.
      Citations: 21     Fields:    Translation:Humans
    258. Kamat AM, Agarwal P, Bivalacqua T, Chisolm S, Daneshmand S, Doroshow JH, Efstathiou JA, Galsky M, Iyer G, Kassouf W, Shah J, Taylor J, Williams SB, Quale DZ, Rosenberg JE. Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank. Bladder Cancer. 2016 Apr 27; 2(2):203-213. PMID: 27376139; PMCID: PMC4927866.
      Citations: 1     
    259. Kamat AM, Cookson M, Witjes JA, Grossman HB, Stenzl A. The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer - A New Analysis. Bladder Cancer. 2016 Apr 27; 2(2):273-278. PMID: 27376146; PMCID: PMC4927917.
      Citations: 16     
    260. Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ. Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2016 Apr 27; 2(2):165-202. PMID: 27376138; PMCID: PMC4927845.
      Citations: 9     
    261. Kamat AM, Karakiewicz PI, Lawrentschuk N, Novara G, Raman JD, Xylinas E, Mbeutcha A, Roupr?t M, Seitz C, Shariat SF. Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World J Urol. 2017 Mar; 35(3):337-353. PMID: 27101100.
      Citations: 24     Fields:    Translation:Humans
    262. Jinesh GG, Taoka R, Zhang Q, Gorantla S, Kamat AM. Novel PKC-? to p47 phox interaction is necessary for transformation from blebbishields. Sci Rep. 2016 Apr 04; 6:23965. PMID: 27040869; PMCID: PMC4819220.
      Citations: 12     Fields:    Translation:HumansCells
    263. Takeuchi H, Taoka R, Mmeje CO, Jinesh GG, Safe S, Kamat AM. CDODA-Me decreases specificity protein transcription factors and induces apoptosis in bladder cancer cells through induction of reactive oxygen species. Urol Oncol. 2016 08; 34(8):337.e11-8. PMID: 27038699.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    264. Williams SB, Kamat AM. Optimum management of non-muscle-invasive micropapillary variant urothelial carcinoma: possibility for missed chance of cure? BJU Int. 2016 09; 118(3):349-50. PMID: 26917454.
      Citations: 1     Fields:    Translation:Humans
    265. Guo CC, Dadhania V, Zhang L, Majewski T, Bondaruk J, Sykulski M, Wronowska W, Gambin A, Wang Y, Zhang S, Fuentes-Mattei E, Kamat AM, Dinney C, Siefker-Radtke A, Choi W, Baggerly KA, McConkey D, Weinstein JN, Czerniak B. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. Eur Urol. 2016 10; 70(4):611-620. PMID: 26988609; PMCID: PMC5804336.
      Citations: 52     Fields:    Translation:HumansCells
    266. Jinesh GG, Kamat AM. Blebbishield emergency program: an apoptotic route to cellular transformation. Cell Death Differ. 2016 May; 23(5):757-8. PMID: 26967969; PMCID: PMC4832111.
      Citations: 10     Fields:    Translation:Humans
    267. Parker WP, Ho PL, Boorjian SA, Melquist JJ, Thapa P, Holzbeierlein JM, Frank I, Kamat AM, Lee EK. The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy. World J Urol. 2016 Nov; 34(11):1561-1566. PMID: 26943643.
      Citations: 1     Fields:    Translation:Humans
    268. Kamat AM. Corrigendum re: "Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Gu?rin" [Eur Urol 2016;69:197-200]. Eur Urol. 2016 07; 70(1):e26. PMID: 27302298.
      Citations: 1     Fields:    
    269. Mmeje CO, Guo CC, Shah JB, Navai N, Grossman HB, Dinney CP, Kamat AM. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Gu?rin Therapy: Implication for Clinical Trial Design. Eur Urol. 2016 11; 70(5):778-785. PMID: 26922408; PMCID: PMC5115993.
      Citations: 3     Fields:    Translation:Humans
    270. Williams SB, Kamat AM. Re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Gu?rin. Eur Urol 2016;69:60-9. Eur Urol. 2016 06; 69(6):e121-2. PMID: 26874808.
      Citations: 1     Fields:    Translation:HumansCells
    271. Jinesh GG, Molina JR, Huang L, Laing NM, Mills GB, Bar-Eli M, Kamat AM. Mitochondrial oligomers boost glycolysis in cancer stem cells to facilitate blebbishield-mediated transformation after apoptosis. Cell Death Discov. 2016; 2:16003. PMID: 27551498; PMCID: PMC4979437.
      Citations: 13     
    272. Jinesh GG, Kamat AM. Endocytosis and serpentine filopodia drive blebbishield-mediated resurrection of apoptotic cancer stem cells. Cell Death Discov. 2016; 2. PMID: 27226900; PMCID: PMC4876976.
      Citations: 14     
    273. Kamat AM, Sylvester RJ, B?hle A, Palou J, Lamm DL, Brausi M, Soloway M, Persad R, Buckley R, Colombel M, Witjes JA. Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. J Clin Oncol. 2016 06 01; 34(16):1935-44. PMID: 26811532; PMCID: PMC5321095.
      Citations: 74     Fields:    Translation:Humans
    274. Figueroa JD, Middlebrooks CD, Banday AR, Ye Y, Garcia-Closas M, Chatterjee N, Koutros S, Kiemeney LA, Rafnar T, Bishop T, Furberg H, Matullo G, Golka K, Taylor JA, Fletcher T, Siddiq A, Cortessis VK, Kooperberg C, Benhamou S, Prescott J, Porru S, Dinney CP, Baris D, Purdue MP, Jacobs EJ, Albanes D, Wang Z, Chung CC, Vermeulen SH, Aben KK, Galesloot TE, Thorleifsson G, Sulem P, Stefansson K, Kiltie AE, Harland M, Teo M, Offit K, Vijai J, Bajorin D, Kopp R, Fiorito G, Guarrera S, Sacerdote C, Selinski S, Hengstler JG, Gerullis H, Blaszkewicz M, Castelao JE, Martinez ME, Cordeiro P, Xu Z, Panduri V, Gurzau E, Koppova K, Bueno-De-Mesquita HB, Krogh V, Travis RC, Brennan P, Riboli E, Conti D, Stern MC, Pike MC, Van Den Berg D, Yuan JM, Hohensee C, Jeppson RP, Turman C, De Vivo I, Giovannucci E, Hunter DJ, Kraft P, Lindstrom S, Carta A, Pavanello S, Arici C, Mastrangelo G, Kamat AM, Zhang L, Gong Y, Pu X, Hutchinson A, Burdett L, Wheeler WA, Karagas MR, Johnson A, Schned A, Monawar Hosain GM, Schwenn M, Carrato A, Andriole G, Grubb R, Black A, Diver WR, Gapstur SM, Weinstein S, Virtamo J, Haiman CA, Landi MT, Caporaso NE, Fraumeni JF, Vineis P, Wu X, Chanock SJ, Silverman DT, Prokunina-Olsson L, Rothman N, Gago-Dominguez M, Cussenot O, Malats N, Ovsiannikov D, Calaza M, Kumar R, Ljungberg B, Clavel-Chapelon F, Weiderpass E, Dorronsoro M, Tj?nneland A, Chang-Claude J, Cancel-Tassin G, Roupret M, Comperat E, Kogevinas M, Tard?n A, Serra C, Garc?a-Closas R, Lloreta J. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Hum Mol Genet. 2016 Mar 15; 25(6):1203-14. PMID: 26732427; PMCID: PMC4817084.
      Citations: 9     Fields:    Translation:HumansCells
    275. Jinesh GG, Laing NM, Kamat AM. Smac mimetic with TNF-a targets Pim-1 isoforms and reactive oxygen species production to abrogate transformation from blebbishields. Biochem J. 2016 Jan 01; 473(1):99-107. PMID: 26508734.
      Citations: 11     Fields:    Translation:HumansCells
    276. Patel S, Dinh T, Noah-Vanhoucke J, Rengarajan B, Mayo K, Clark PE, Kamat AM, Lee CT, Sexton WJ, Steinberg GD. Novel Simulation Model of Non-Muscle Invasive Bladder Cancer: A Platform for a Virtual Randomized Trial of Conservative Therapy vs. Cystectomy in BCG Refractory Patients. Bladder Cancer. 2015 Oct 26; 1(2):143-150. PMID: 27376114; PMCID: PMC4927810.
      Citations: 1     
    277. Krughoff K, Lhungay TP, Barqawi Z, O'Donnell C, Kamat A, Wilson S. The Prognostic Value of Previous Irradiation on Survival of Bladder Cancer Patients. Bladder Cancer. 2015 Oct 26; 1(2):171-179. PMID: 27376117; PMCID: PMC4927829.
      Citations:    
    278. Morales EE, Aggarwal BB, Kamat AM. Natural Compounds Targeting STAT3 Mediated Inflammation. Eur Urol. 2016 Mar; 69(3):405-6. PMID: 26454706.
      Citations: 1     Fields:    Translation:Cells
    279. Ho PL, Willis DL, Patil J, Xiao L, Williams SB, Melquist JJ, Tart K, Parikh S, Shah JB, Delacroix SE, Navai N, Siefker-Radtke A, Dinney CP, Pisters LL, Kamat AM. Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. Urol Oncol. 2016 Feb; 34(2):59.e1-8. PMID: 26421586.
      Citations: 18     Fields:    Translation:Humans
    280. McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-na?ve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol. 2016 05; 69(5):855-62. PMID: 26343003; PMCID: PMC4775435.
      Citations: 97     Fields:    Translation:HumansCellsCTClinical Trials
    281. Williams SB, Lamm DL, Kamat AM. Re: Richard J. Sylvester, Willem Oosterlinck, Sten Holmang, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.05.050. Eur Urol. 2015 Dec; 68(6):e127. PMID: 26318707.
      Citations:    Fields:    Translation:Humans
    282. Takeuchi H, Mmeje CO, Jinesh GG, Taoka R, Kamat AM. Sequential gemcitabine and tamoxifen treatment enhances apoptosis and blocks transformation in bladder cancer cells. Oncol Rep. 2015 Nov; 34(5):2738-44. PMID: 26323344; PMCID: PMC4583834.
      Citations: 9     Fields:    Translation:HumansCells
    283. Dhillon J, Liang Y, Kamat AM, Siefker-Radtke A, Dinney CP, Czerniak B, Guo CC. Urachal carcinoma: a pathologic and clinical study of 46 cases. Hum Pathol. 2015 Dec; 46(12):1808-14. PMID: 26364859; PMCID: PMC4824311.
      Citations: 29     Fields:    Translation:Humans
    284. Kamat AM, Urbauer DL. Reply from Authors re: Tahlita C.M. Zuiverloon, Ellen C. Zwarthoff. Predicting Response to Intravesical Bacillus Calmette-Gu?rin Immunotherapy: Are We Moving Forward? Eur Urol 2016;69:201-2: The Goal: Individualized Bacillus Calmette-Gu?rin Therapy. Eur Urol. 2016 Feb; 69(2):203. PMID: 26260001.
      Citations:    Fields:    Translation:HumansCells
    285. Morales A, Kamat A, Steinberg G, Given R, Amrhein J, Cohen Z, Herr H. Re: Herr et al.: BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: A prospective cohort outcomes study (Urol Oncol 2015; 33: 108.el-108.e4). Urol Oncol. 2015 Aug; 33(8):335-6. PMID: 26182846.
      Citations:    Fields:    Translation:Humans
    286. Pierzynski JA, Hildebrandt MA, Kamat AM, Lin J, Ye Y, Dinney CP, Wu X. Genetic Variants in the Wnt/?-Catenin Signaling Pathway as Indicators of Bladder Cancer Risk. J Urol. 2015 Dec; 194(6):1771-6. PMID: 26173102; PMCID: PMC5087323.
      Citations: 24     Fields:    Translation:HumansCells
    287. Kamat AM, Willis DL, Dickstein RJ, Anderson R, Katz RL, Wu X, Barton Grossman H, Dinney CP, Nogueras-Gonz?lez G. Novel fluorescence in?situ hybridization-based definition of bacille Calmette-Gu?rin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. BJU Int. 2016 May; 117(5):754-60. PMID: 26032953; PMCID: PMC4666834.
      Citations: 12     Fields:    Translation:Humans
    288. Kamat AM, Briggman J, Urbauer DL, Svatek R, Anderson R, Grossman HB, Prat F, Dinney CP, Nogueras Gonz?lez GM. Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Gu?rin. Eur Urol. 2016 02; 69(2):197-200. PMID: 26119560; PMCID: PMC4691211.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    289. Breen V, Kasabov N, Kamat AM, Jacobson E, Suttie JM, O'Sullivan PJ, Kavalieris L, Darling DG. A holistic comparative analysis of diagnostic tests for urothelial carcinoma: a study of Cxbladder Detect, UroVysion? FISH, NMP22? and cytology based on imputation of multiple datasets. BMC Med Res Methodol. 2015 May 12; 15:45. PMID: 25962444; PMCID: PMC4494166.
      Citations: 13     Fields:    Translation:Humans
    290. Williams SB, Ye Y, Huang M, Chang DW, Kamat AM, Pu X, Dinney CP, Wu X. Mitochondrial DNA Content as Risk Factor for Bladder Cancer and Its Association with Mitochondrial DNA Polymorphisms. Cancer Prev Res (Phila). 2015 Jul; 8(7):607-13. PMID: 25896234; PMCID: PMC4490997.
      Citations: 6     Fields:    Translation:Humans
    291. Kamat A, Lee JY, Goldstein GH, Newman JG, Storm PB, Palmer JN, Adappa ND. Reconstructive challenges in the extended endoscopic transclival approach. J Laryngol Otol. 2015 May; 129(5):468-72. PMID: 25827753.
      Citations: 3     Fields:    Translation:Humans
    292. Lerner SP, Dinney C, Kamat A, Bivalacqua TJ, Nielsen M, O'Donnell M, Schoenberg MP, Steinberg G. Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG. Bladder Cancer. 2015 Mar 30; 1(1):29-30. PMID: 26807434; PMCID: PMC4720147.
      Citations: 30     
    293. Kamat AM, Flaig TW, Grossman HB, Konety B, Lamm D, O'Donnell MA, Uchio E, Efstathiou JA, Taylor JA. Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol. 2015 04; 12(4):225-35. PMID: 25800393.
      Citations: 51     Fields:    Translation:Humans
    294. Taoka R, Williams SB, Ho PL, Kamat AM. In-vitro cytocidal effect of water on bladder cancer cells: The potential role for intraperitoneal lavage during radical cystectomy. Can Urol Assoc J. 2015 Mar-Apr; 9(3-4):E109-13. PMID: 25844095; PMCID: PMC4374995.
      Citations: 5     
    295. Fritsche HM, Burger M, Svatek RS, Novara G, Skinner E, Denzinger S, Isbarn H, Volkmer BG, Montorsi F, Otto W, Izawa JI, Ficarra V, Lerner S, Sagalowsky AI, Schoenberg M, Kamat A, Dinney CP, Lotan Y, Shariat SF, Jeldres C, Karakiewicz PI, Fradet Y, Bastian PJ, Kassouf W, Tilki D, Capitanio U. Corrigendum to "Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort" [Eur Urol 2010;57:300-9]. Eur Urol. 2015 Jul; 68(1):171. PMID: 26088736.
      Citations: 2     Fields:    
    296. Ho PL, Williams SB, Kamat AM. Immune therapies in non-muscle invasive bladder cancer. Curr Treat Options Oncol. 2015 Feb; 16(2):5. PMID: 25757877.
      Citations: 5     Fields:    Translation:Humans
    297. Williams SB, Kamat AM, Lamm DL. Pelvic recurrence after radical cystectomy: a call to arms. BJU Int. 2015 Aug; 116(2):172-3. PMID: 25307493.
      Citations: 1     Fields:    Translation:Humans
    298. Willis D, Kamat AM. Nonurothelial bladder cancer and rare variant histologies. Hematol Oncol Clin North Am. 2015 Apr; 29(2):237-52, viii. PMID: 25836932.
      Citations: 20     Fields:    Translation:Humans
    299. Kamat A. Commentary on "Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Gu?rin immunotherapy." Lee JY, Diaz RR, Cho KS, Lim MS, Chung JS, Kim WT, Ham WS, Choi YD, Department of Urology, Yonsei University College of Medicine, Seoul, Republic of Korea; Severance Hospital and Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.: J Urol 2013; 190(4):1192-9. doi:10.1016/j.juro.2013.04.077. [Epub 2013 May 3]. Urol Oncol. 2015 Jan; 33(1):46. PMID: 25528637.
      Citations:    Fields:    Translation:Humans
    300. Kamat A. Commentary on "The impact of intravesical gemcitabine and 1/3 dose bacillus Calmette-Gu?rin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: Results of a prospective, randomized, phase II trial." Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I, Rink M, Schmid M, Kluth LA, Pappagallo G, Sogni F, Sanguedolce F, Schiavina R, Martorana G, Shariat SF, Chun F.: J Urol 2013; 190(3):857-62. doi:10.1016/j.juro.2013.03.097. [Epub 2013 Mar 29]. Urol Oncol. 2015 Jan; 33(1):46-47. PMID: 25528638.
      Citations:    Fields:    Translation:Humans
    301. Kamat A. Commentary on "Impact of statin use on oncologic outcomes in patients with urothelial carcinoma ofthe bladder treated with radical cystectomy." da Silva RD, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Chade D, Guglielmetti GB, Pycha A, Lotan Y, Karakiewicz PI, Sun M, Fajkovic H, Zerbib M, Scherr DS, Shariat SF, Department of Urology and Division of Medical Oncology, Weill Cornell Medical College, New York - Presbyterian Hospital, New York, New York 10065, USA.: J Urol 2013; 190(2):487-92. doi:10.1016/j.juro.2013.02.003. [Epub 2013 Feb 8]. Urol Oncol. 2015 Jan; 33(1):47-48. PMID: 25528639.
      Citations:    Fields:    Translation:Humans
    302. Li W, Liang Y, Deavers MT, Kamat AM, Matin SF, Dinney CP, Czerniak B, Guo CC. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol. 2014 Dec; 142(6):864-71. PMID: 25389341.
      Citations: 8     Fields:    Translation:Humans
    303. Parker WP, Ho PL, Melquist JJ, Scott K, Holzbeierlein JM, Lopez-Corona E, Kamat AM, Lee EK. The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival. J Urol. 2015 May; 193(5):1494-9. PMID: 25451834.
      Citations: 5     Fields:    Translation:Humans
    304. Kamat A. Commentary on "Upper tract imaging surveillance is not effective in diagnosing upper tract recurrence in patients followed fornonmuscle invasive bladder cancer." Sternberg IA, Chen LY, Herr HW, Donat SM, Bochner BH, Dalbagni G, Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.: J Urol 2013; 190(4):1187-91. doi:10.1016/j.juro.2013.05.020. [Epub 2013 May 13]. Urol Oncol. 2014 Nov; 32(8):1348-9. PMID: 25488383.
      Citations: 1     Fields:    Translation:Humans
    305. Nawroth R, Goebell PJ, Kamat AM, Kiemeney LA, Schmitz-Dr?ger BJ. Current concepts--future needs: the 10th Annual Meeting of the International Bladder Cancer Network (IBCN) in Nijmegen, The Netherlands, September 20th to 22nd, 2012. Urol Oncol. 2014 Oct; 32(7):1049-50. PMID: 25443142.
      Citations:    Fields:    Translation:Humans
    306. Kamat AM, Vlahou A, Taylor JA, Hudson ML, Pesch B, Ingersoll MA, van Rhijn B, Kassouf W, Barton Grossman H, Chandra A, Sanchez-Carbayo M, Todenh?fer T, Behrens T, Goebell PJ, Palou J, Schmitz-Dr?ger BJ. Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer. Urol Oncol. 2014 Oct; 32(7):1069-77. PMID: 25306288.
      Citations: 14     Fields:    Translation:Humans
    307. Morales A, Herr H, Steinberg G, Given R, Cohen Z, Amrhein J, Kamat AM. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Gu?rin. J Urol. 2015 Apr; 193(4):1135-43. PMID: 25286009.
      Citations: 22     Fields:    Translation:HumansCells
    308. Thomas AZ, Kamat AM. Venous thromboembolism and bleeding risk in bladder cancer. Oncology (Williston Park). 2014 Oct; 28(10):854-5, 861. PMID: 25323611.
      Citations:    Fields:    Translation:Humans
    309. Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, Grossman HB, Kamat AM, Konety BR, Lee CT, Pohar KS, Pruthi RS, Resnick MJ, Smith ND, Witjes JA, Schoenberg MP, Steinberg GD. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol. 2014 Oct; 11(10):589-96. PMID: 25245244.
      Citations: 18     Fields:    Translation:Humans
    310. Willis DL, Fernandez MI, Dickstein RJ, Parikh S, Shah JB, Pisters LL, Guo CC, Henderson S, Czerniak BA, Grossman HB, Dinney CP, Kamat AM. Clinical outcomes of cT1 micropapillary bladder cancer. J Urol. 2015 Apr; 193(4):1129-34. PMID: 25254936; PMCID: PMC4687395.
      Citations: 26     Fields:    Translation:Humans
    311. Porten SP, Willis D, Kamat AM. Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer. Curr Opin Urol. 2014 Sep; 24(5):517-23. PMID: 24921905.
      Citations: 20     Fields:    Translation:Humans
    312. Svatek RS, Clinton TN, Wilson CA, Kamat AM, Grossman HB, Dinney CP, Shah JB. Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy. Urology. 2014 Nov; 84(5):1147-51. PMID: 25174656.
      Citations: 8     Fields:    Translation:Humans
    313. Kamat AM, Sylvester RJ, Black P, Droller M, Godoy G, Hudson MA, Kassouf W, Knowles MA, Seiler R, Goebell PJ, Junker K, Schulz WA, Schmitz-Dr?ger BJ. Assessing the quality of studies on the diagnostic accuracy of tumor markers. Urol Oncol. 2014 Oct; 32(7):1051-60. PMID: 25159014; PMCID: PMC4524775.
      Citations: 3     Fields:    Translation:Humans
    314. Amrhein J, Kamat AM, Morales A. Re: Jarow JP et al.: Clinical trial design for the development of new therapies for non-muscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop (Urology 2014;83:262-265). Urology. 2014 Aug; 84(2):494-5. PMID: 25065995.
      Citations: 3     Fields:    Translation:Humans
    315. Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, Knowles M, Theodorescu D, Czerniak BA, Efstathiou JA, Albert ML, Sridhar SS, Margulis V, Matin SF, Galsky MD, Hansel D, Kamat AM, Flaig TW, Smith AB, Messing E, Zipursky Quale D, Lotan Y. Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. Urol Oncol. 2015 Feb; 33(2):53-64. PMID: 25065704; PMCID: PMC6776416.
      Citations: 4     Fields:    Translation:HumansAnimals
    316. Wang Z, Zhu B, Zhang M, Parikh H, Jia J, Chung CC, Sampson JN, Hoskins JW, Hutchinson A, Burdette L, Ibrahim A, Hautman C, Raj PS, Abnet CC, Adjei AA, Ahlbom A, Albanes D, Allen NE, Ambrosone CB, Aldrich M, Amiano P, Amos C, Andersson U, Andriole G, Andrulis IL, Arici C, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Beane Freeman LE, Berg CD, Berndt SI, Bertazzi PA, Biritwum RB, Black A, Blot W, Boeing H, Boffetta P, Bolton K, Boutron-Ruault MC, Bracci PM, Brennan P, Brinton LA, Brotzman M, Bueno-de-Mesquita HB, Buring JE, Butler MA, Cai Q, Canzian F, Cao G, Caporaso NE, Carreon T, Carta A, Chang GC, Chang IS, Chang-Claude J, Che X, Chen CJ, Chen CY, Chen CH, Chen C, Chen KY, Chen YM, Chokkalingam AP, Chu LW, Clavel-Chapelon F, Colditz GA, Colt JS, Conti D, Cook MB, Cortessis VK, Crawford ED, Davis FG, De Vivo I, Deng X, Ding T, Dinney CP, Di Stefano AL, Diver WR, Duell EJ, Elena JW, Fan JH, Feigelson HS, Feychting M, Figueroa JD, Flanagan AM, Fraumeni JF, Freedman ND, Fridley BL, Fuchs CS, Gallinger S, Gapstur SM, Garcia-Closas M, Gastier-Foster JM, Gaziano JM, Gerhard DS, Giffen CA, Giles GG, Gillanders EM, Giovannucci EL, Goggins M, Gokgoz N, Goldstein AM, Gonzalez C, Gorlick R, Greene MH, Gross M, Grossman HB, Grubb R, Gu J, Guan P, Haiman CA, Hallmans G, Hankinson SE, Harris CC, Hartge P, Hattinger C, Hayes RB, He Q, Helman L, Henderson BE, Henriksson R, Hoffman-Bolton J, Hohensee C, Holly EA, Hong YC, Hoover RN, Hosgood HD, Hsiao CF, Hsing AW, Hsiung CA, Hu N, Hu W, Hu Z, Huang MS, Hunter DJ, Inskip PD, Ito H, Jacobs EJ, Jacobs KB, Jenab M, Ji BT, Johansen C, Johansson M, Johnson A, Kaaks R, Kamat AM, Kamineni A, Karagas M, Khanna C, Khaw KT, Kim C, Kim IS, Kim JH, Kim YH, Kim YC, Kim YT, Kang CH, Jung YJ, Kitahara CM, Klein AP, Klein R, Koh WP, Kohno T, Kolonel LN, Kooperberg C, Kratz CP, Krogh V, Kunitoh H, Kurtz RC, Kurucu N, Lan Q, Lau CC, Lecanda F, Lee KM, Lee MP, Le Marchand L, Lerner SP, Li D, Liao LM, Lim WY, Lin D, Lin J, Lindstrom S, Linet MS, Lissowska J, Liu J, Lu D, Ma J, Mannisto S, Marina N, Mastrangelo G, Matsuo K, McGlynn KA, McKean-Cowdin R, McNeill LH, McWilliams RR, Melin BS, Meltzer PS, Mensah JE, Miao X, Michaud DS, Mondul AM, Moore LE, Muir K, Niwa S, Olson SH, Orr N, Panico S, Park JY, Patel AV, Patino-Garcia A, Pavanello S, Peeters PH, Peplonska B, Peters U, Petersen GM, Picci P, Pike MC, Porru S, Prescott J, Pu X, Purdue MP, Qiao YL, Rajaraman P, Riboli E, Risch HA, Rodabough RJ, Rothman N, Ruder AM, Ryu JS, Sanson M, Schned A, Schumacher FR, Schwartz AG, Schwartz KL, Schwenn M, Scotlandi K, Seow A, Serra C, Serra M, Sesso HD, Severi G, Shen H, Shen M, Shete S, Shiraishi K, Shu XO, Siddiq A, Sierrasesumaga L, Sierri S, Loon Sihoe AD, Silverman DT, Simon M, Southey MC, Spector L, Spitz M, Stampfer M, Stattin P, Stern MC, Stevens VL, Stolzenberg-Solomon RZ, Stram DO, Strom SS, Su WC, Sung SW, Swerdlow A, Tan W, Tanaka H, Tang W, Tang ZZ, Tay E, Taylor PR, Tettey Y, Thomas DM, Tirabosco R, Tjonneland A, Tobias GS, Toro JR, Travis RC, Trichopoulos D, Troisi R, Truelove A, Tsai YH, Tucker MA, Tumino R, Van Den Berg D, Van Den Eeden SK, Vermeulen R, Vineis P, Visvanathan K, Vogel U, Wang C, Wang C, Wang J, Wang SS, Weinstein SJ, Wentzensen N, Wheeler W, White E, Wiencke JK, Wolk A, Wolpin BM, Wong MP, Wrensch M, Wu C, Wu T, Wu X, Wu YL, Wunder JS, Xu J, Yang HP, Yang PC, Yatabe Y, Ye Y, Yeboah ED, Yin Z, Ying C, Yu CJ, Yu K, Yuan JM, Zanetti KA, Zeleniuch-Jacquotte A, Zheng W, Zhou B, Mirabello L, Savage SA, Kraft P, Chanock SJ, Yeager M, Landi MT, Shi J, Chatterjee N, et al. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet. 2014 Dec 15; 23(24):6616-33. PMID: 25027329; PMCID: PMC4240198.
      Citations: 62     Fields:    Translation:HumansCells
    317. Kamat AM, Lamm DL. Predicting response to bacillus Calmette-Gu?rin: time to look beyond the ages. Eur Urol. 2014 Oct; 66(4):702-3. PMID: 24968969.
      Citations:    Fields:    Translation:Humans
    318. Willis DL, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA, Plimack ER, Koppie TM, McConkey DJ, Dinney CP, Hoffman VA, Droller MJ, Messing E, Kamat AM. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol Oncol. 2014 Aug; 32(6):826-32. PMID: 24931270; PMCID: PMC4687398.
      Citations: 15     Fields:    Translation:Humans
    319. Hoang AN, Agarwal PK, Walton-Diaz A, Wood CG, Metwalli AR, Kassouf W, Brown GA, Black PC, Urbauer DL, Grossman HB, Dinney CP, Kamat AM. Clinical significance of ureteric 'skip lesions' at the time of radical cystectomy: the M.D. Anderson experience and literature review. BJU Int. 2014 May; 113(5b):E28-33. PMID: 24053608.
      Citations: 7     Fields:    Translation:Humans
    320. Pisters AL, Kamat AM, Wei W, Leibovici D, Liu J, Grossman HB, Butler CE. Reply: To PMID 24768009. Urology. 2014 Jun; 83(6):1432. PMID: 24768020.
      Citations:    Fields:    Translation:Humans
    321. Pisters AL, Kamat AM, Wei W, Leibovici D, Liu J, Grossman HB, Butler CE. Anterior fascial fixation does not reduce the parastomal hernia rate after radical cystectomy and ileal conduit. Urology. 2014 Jun; 83(6):1427-31. PMID: 24768021.
      Citations: 3     Fields:    Translation:Humans
    322. Onaiwu CO, Ramirez PT, Kamat A, Pagliaro LC, Euscher EE, Schmeler KM. Invasive extramammary Paget's disease of the bladder diagnosed 18?years after noninvasive extramammary Paget's disease of the vulva. Gynecol Oncol Case Rep. 2014 Apr; 8:27-9. PMID: 24809008; PMCID: PMC4009448.
      Citations: 6     
    323. Gray PJ, Lin CC, Jemal A, Shipley WU, Fedewa SA, Kibel AS, Rosenberg JE, Kamat AM, Virgo KS, Blute ML, Zietman AL, Efstathiou JA. Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1048-56. PMID: 24661658.
      Citations: 24     Fields:    Translation:Humans
    324. Kamat AM, Witjes JA, Brausi M, Soloway M, Lamm D, Persad R, Buckley R, B?hle A, Colombel M, Palou J. Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. J Urol. 2014 Aug; 192(2):305-15. PMID: 24681333; PMCID: PMC4687397.
      Citations: 36     Fields:    Translation:Humans
    325. Liang Y, Heitzman J, Kamat AM, Dinney CP, Czerniak B, Guo CC. Differential expression of GATA-3 in urothelial carcinoma variants. Hum Pathol. 2014 Jul; 45(7):1466-72. PMID: 24745616.
      Citations: 11     Fields:    Translation:Humans
    326. Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, Jonasch E, Dinney CP, Matin SF. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer. 2014 Jun 15; 120(12):1794-9. PMID: 24633966; PMCID: PMC4440575.
      Citations: 54     Fields:    Translation:Humans
    327. Goodwin Jinesh G, Willis DL, Kamat AM. Bladder cancer stem cells: biological and therapeutic perspectives. Curr Stem Cell Res Ther. 2014 Mar; 9(2):89-101. PMID: 24236543.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    328. Lee CT, Chang SS, Kamat AM, Amiel G, Beard TL, Fergany A, Karnes RJ, Kurz A, Menon V, Sexton WJ, Slaton JW, Svatek RS, Wilson SS, Techner L, Bihrle R, Steinberg GD, Koch M. Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial. Eur Urol. 2014 Aug; 66(2):265-72. PMID: 24630419.
      Citations: 53     Fields:    Translation:Humans
    329. Messer JC, Shariat SF, Dinney CP, Novara G, Fritsche HM, Izawa JI, Lotan Y, Skinner EC, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Wei C, Lerner SP, Curiel TJ, Kamat AM, Svatek RS, Fradet Y, Kassouf W, Karakiewicz PI. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology. 2014 Apr; 83(4):863-7. PMID: 24485993.
      Citations: 22     Fields:    Translation:Humans
    330. van Rhijn B, Pesch B, Hudson MA, Chandra A, Ingersoll MA, Kassouf W, Taylor J, Vlahou A, Critelli R, Grossman HB, Sanchez-Carbayo M, Kamat A, Schmitz-Dr?ger BJ, Todenh?fer T, Palou J, Behrens T. Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer. Urol Oncol. 2014 Oct; 32(7):1061-8. PMID: 24411790.
      Citations: 11     Fields:    Translation:Humans
    331. Kauf TL, Svatek RS, Amiel G, Beard TL, Chang SS, Fergany A, Karnes RJ, Koch M, O'Hara J, Lee CT, Sexton WJ, Slaton JW, Steinberg GD, Wilson SS, Techner L, Martin C, Moreno J, Kamat AM. Alvimopan, a peripherally acting ?-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial. J Urol. 2014 Jun; 191(6):1721-7. PMID: 24342144.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    332. Abel EJ, Fisher MB, Matin SF, Kamat AM, Dinney CP, Grossman HB. Delayed ureterectomy after incomplete nephroureterectomy for upper tract urothelial carcinoma: pathologic findings and outcomes. Int Braz J Urol. 2013 Nov-Dec; 39(6):817-22. PMID: 24456786.
      Citations: 1     Fields:    Translation:Humans
    333. Kamat AM, Porten S. Myths and mysteries surrounding bacillus Calmette-Gu?rin therapy for bladder cancer. Eur Urol. 2014 Feb; 65(2):267-9. PMID: 24199712; PMCID: PMC4676267.
      Citations: 11     Fields:    Translation:Humans
    334. Figueroa JD, Ye Y, Siddiq A, Garcia-Closas M, Chatterjee N, Prokunina-Olsson L, Cortessis VK, Kooperberg C, Cussenot O, Benhamou S, Prescott J, Porru S, Dinney CP, Baris D, Purdue M, Jacobs EJ, Albanes D, Wang Z, Deng X, Chung CC, Tang W, Bas Bueno-de-Mesquita H, Trichopoulos D, Weiderpass E, Krogh V, Dorronsoro M, Travis R, Brenan P, Chang-Claude J, Riboli E, Conti D, Gago-Dominguez M, Stern MC, Pike MC, Van Den Berg D, Yuan JM, Hohensee C, Rodabough R, Cancel-Tassin G, Roupret M, Comperat E, Chen C, De Vivo I, Giovannucci E, Hunter DJ, Kraft P, Lindstrom S, Carta A, Pavanello S, Arici C, Mastrangelo G, Kamat AM, Lerner SP, Barton Grossman H, Lin J, Gu J, Pu X, Hutchinson A, Burdette L, Wheeler W, Kogevinas M, Serra C, Carrato A, Lloreta J, Schwenn M, Karagas MR, Johnson A, Schned A, Armenti KR, Hosain GM, Andriole G, Grubb R, Black A, Ryan Diver W, Gapstur SM, Weinstein SJ, Virtamo J, Haiman CA, Landi MT, Caporaso N, Fraumeni JF, Vineis P, Wu X, Silverman DT, Chanock S, Rothman N, Malats N, Ljungberg B, Clavel-Chapelon F, Tj?nneland A, Tard?n A, Garc?a-Closas R. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet. 2014 Mar 01; 23(5):1387-98. PMID: 24163127; PMCID: PMC3919005.
      Citations: 74     Fields:    Translation:Humans
    335. Willis DL, Porten SP, Kamat AM. Should histologic variants alter definitive treatment of bladder cancer? Curr Opin Urol. 2013 Sep; 23(5):435-43. PMID: 23880739.
      Citations: 9     Fields:    Translation:Humans
    336. Wood DP. Re: A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. J Urol. 2013 Dec; 190(6):2019. PMID: 24209516.
      Citations:    Fields:    Translation:Humans
    337. Lamm D, Persad R, Brausi M, Buckley R, Witjes JA, Kamat AM, Soloway M, Palou J, B?hle A, Colombel M. Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition. J Urol. 2014 Jan; 191(1):20-7. PMID: 23973937.
      Citations: 35     Fields:    Translation:Humans
    338. Gong Y, Ye Y, Lin J, Chang DW, Kamat AM, Wu X, Fern?ndez MI. ?-H2AX level in peripheral blood lymphocytes as a risk predictor for bladder cancer. Carcinogenesis. 2013 Nov; 34(11):2543-7. PMID: 23946494; PMCID: PMC3810842.
      Citations: 7     Fields:    Translation:HumansCells
    339. Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, Cai J, Groshen S, Siefker-Radtke A, Millikan RE, Czerniak B, Navai N, Wszolek MF, Kamat AM, Dinney CP. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol. 2014 Jan; 191(1):40-7. PMID: 23911605; PMCID: PMC4158919.
      Citations: 60     Fields:    Translation:Humans
    340. See WA. Commentary on "The value of transurethral bladder biopsy after intravesical bacillus Calmette-Gu?rin instillation therapy for nonmuscle invasive bladder cancer: a retrospective, single center study and cumulative analysis of the literature." Swietek N, Waldert M, Rom M, Schatzl G, Wiener HG, Susani M, Klatte T. Department of Urology, Medical University of Vienna, Vienna, Austria: J Urol 2012;188(3):748-53 [Epub 2012 Jul 20]. Urol Oncol. 2013 Jul; 31(5):715-6. PMID: 23796199.
      Citations:    Fields:    Translation:Humans
    341. See WA. Commentary on "Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?" Mertens LS, Meijer RP, Kerst JM, Bergman AM, van Tinteren H, van Rhijn BW, Horenblas S, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands: J Urol 2012;188(4):1108-13 [Epub 2012 Aug 15]. Urol Oncol. 2013 Jul; 31(5):716-7. PMID: 23796200.
      Citations:    Fields:    Translation:Humans
    342. Kamat AM. Commentary on "Predictive capacity of four comorbidity indices estimating perioperative mortality after radical cystectomy for urothelial carcinoma of the bladder." Mayr R, May M, Martini T, Lodde M, Pycha A, Comploj E, Wieland WF, Denzinger S, Otto W, Burger M, Fritsche HM. Department of Urology, Central Hospital of Bolzano, Bolzano, Italy: BJU Int 2012;110(6 Pt B):E222-7 [Epub 2012 Feb 7]. Urol Oncol. 2013 Jul; 31(5):718-9. PMID: 23796203.
      Citations: 2     Fields:    Translation:Humans
    343. Kamat AM. Commentary on "The clinical epidemiology of urachal carcinoma: results of a large, population based study." Bruins HM, Visser O, Ploeg M, Hulsbergen-van de Kaa CA, Kiemeney LA, Witjes JA, Department of Urology, Radboud University Medical Centre, Utrecht, The Netherlands: J Urol 2012;188(4):1102-7 [Epub 2012 Aug 15]. Urol Oncol. 2013 Jul; 31(5):720. PMID: 23796205.
      Citations: 2     Fields:    Translation:Humans
    344. Kamat AM. Commentary on "Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience." Yafi FA, Aprikian AG, Fradet Y, Chin JL, Izawa J, Rendon R, Estey E, Fairey A, Cagiannos I, Lacombe L, Lattouf JB, Bell D, Saad F, Drachenberg D, Kassouf W. Department of Surgery (Urology), McGill University, Quebec, Canada: BJU Int 2012;110(9):1317-23 [Epub 2012 Apr 13]. Urol Oncol. 2013 Jul; 31(5):717-8. PMID: 23796202.
      Citations: 3     Fields:    Translation:Humans
    345. See WA. Commentary on "Plasma carotenoids and vitamin C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition." Ros MM, Bueno de Mesquita HB, Kampman E, Aben KK, B?chner FL, Jansen EH, van Gils CH, Egevad L, Overvad K, Tj?nneland A, Roswall N, Boutron Ruault MC, Kvaskoff M, Perquier F, Kaaks R, Chang Claude J, Weikert S, Boeing H, Trichopoulou A, Lagiou P, Dilis V, Palli D, Pala V, Sacerdote C, Tumino R, Panico S, Peeters PH, Gram IT, Skeie G, Huerta JM, Barricarte A, Quir?s JR, S?nchez MJ, Buckland G, Larra?aga N, Ehrnstr?m R, Wallstr?m P, Ljungberg B, Hallmans G, Key TJ, Allen NE, Khaw KT, Wareham N, Brennan P, Riboli E, Kiemeney LA, National Institute for Public Health and the Environment, Bilthoven, Netherlands: Am J Clin Nutr 2012;96(4):902-10 [Epub 2012 Sep 5]. Urol Oncol. 2013 Jul; 31(5):714-5. PMID: 23796198.
      Citations: 3     Fields:    Translation:Humans
    346. See WA. Commentary on "Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome." Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E, Parry S, Goldblatt J, Lipton L, Winship I, Leggett B, Tucker KM, Giles GG, Buchanan DD, Clendenning M, Rosty C, Arnold J, Levine AJ, Haile RW, Gallinger S, Le Marchand L, Newcomb PA, Hopper JL, Jenkins MA, Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, Melbourne School of Population Health, The University of Melbourne, Victoria, Australia: J Natl Cancer Inst 2012;104(18):1363-72 [Epub 2012 Aug 28]. Urol Oncol. 2013 Jul; 31(5):716. PMID: 23796201.
      Citations: 6     Fields:    Translation:HumansCells
    347. Kamat AM. Commentary on "Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma." Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G, University of Pennsylvania, Philadelphia, PA: J Clin Oncol 2012;30(28):3545-51 [Epub 2012 Aug 27]. Urol Oncol. 2013 Jul; 31(5):719. PMID: 23796204.
      Citations: 4     Fields:    Translation:Humans
    348. Lee EK, Jinesh G G, Laing NM, Choi W, McConkey DJ, Kamat AM. A Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin. Cancer Biol Ther. 2013 Sep; 14(9):812-22. PMID: 23792592; PMCID: PMC3909550.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    349. Wang J, Wu X, Kamat A, Barton Grossman H, Dinney CP, Lin J. Fluid intake, genetic variants of UDP-glucuronosyltransferases, and bladder cancer risk. Br J Cancer. 2013 Jun 11; 108(11):2372-80. PMID: 23632476; PMCID: PMC3681021.
      Citations: 13     Fields:    Translation:Humans
    350. Lee EK, Ye Y, Kamat AM, Wu X. Genetic variations in regulator of G-protein signaling (RGS) confer risk of bladder cancer. Cancer. 2013 May 01; 119(9):1643-51. PMID: 23529717; PMCID: PMC4004376.
      Citations: 8     Fields:    Translation:Humans
    351. Dinney CP, Fisher MB, Navai N, O'Donnell MA, Cutler D, Abraham A, Young S, Hutchins B, Caceres M, Kishnani N, Sode G, Cullen C, Zhang G, Grossman HB, Kamat AM, Gonzales M, Kincaid M, Ainslie N, Maneval DC, Wszolek MF, Benedict WF. Phase I trial of intravesical recombinant adenovirus mediated interferon-a2b formulated in Syn3 for Bacillus Calmette-Gu?rin failures in nonmuscle invasive bladder cancer. J Urol. 2013 Sep; 190(3):850-6. PMID: 23507396; PMCID: PMC3951790.
      Citations: 38     Fields:    Translation:HumansCellsCTClinical Trials
    352. Witjes JA, Palou J, Soloway M, Lamm D, Kamat AM, Brausi M, Persad R, Buckley R, Colombel M, B?hle A. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Gu?rin (BCG): results of an international individual patient data survey (IPDS). BJU Int. 2013 Oct; 112(6):742-50. PMID: 23452187; PMCID: PMC3933735.
      Citations: 34     Fields:    Translation:HumansPHPublic Health
    353. Shah JB, Kamat AM. Strategies for optimizing bacillus Calmette-Gu?rin. Urol Clin North Am. 2013 May; 40(2):211-8. PMID: 23540779.
      Citations: 4     Fields:    Translation:Humans
    354. Chauhan S, Goodwin JG, Chauhan S, Manyam G, Wang J, Kamat AM, Boyd DD. ZKSCAN3 is a master transcriptional repressor of autophagy. Mol Cell. 2013 Apr 11; 50(1):16-28. PMID: 23434374; PMCID: PMC3628091.
      Citations: 125     Fields:    Translation:HumansCells
    355. Davis JW, Kamat AM. Lymphadenectomy with robotic cystectomy. Curr Urol Rep. 2013 Feb; 14(1):59-63. PMID: 23138180.
      Citations:    Fields:    Translation:Humans
    356. Wei H, Kamat AM, Aldousari S, Ye Y, Huang M, Dinney CP, Wu X. Genetic variations in the transforming growth factor beta pathway as predictors of bladder cancer risk. PLoS One. 2012; 7(12):e51758. PMID: 23251617; PMCID: PMC3520916.
      Citations: 12     Fields:    Translation:HumansCells
    357. Jinesh GG, Choi W, Shah JB, Lee EK, Willis DL, Kamat AM. Blebbishields, the emergency program for cancer stem cells: sphere formation and tumorigenesis after apoptosis. Cell Death Differ. 2013 Mar; 20(3):382-95. PMID: 23175184; PMCID: PMC3569985.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    358. Apolo AB, Grossman HB, Bajorin D, Steinberg G, Kamat AM. Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. Urol Oncol. 2012 Nov-Dec; 30(6):772-80. PMID: 23218068; PMCID: PMC3524835.
      Citations: 16     Fields:    Translation:Humans
    359. Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, Shariat SF, Xylinas E, Lotan Y, Jenkins LC, Droller M, van Rhijn BW, Karakiewicz PI, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladd, Schmitz-Dr?ger BJ. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. Eur Urol. 2013 Jan; 63(1):4-15. PMID: 23083902.
      Citations: 88     Fields:    Translation:HumansPHPublic Health
    360. Jinesh G G, Kamat AM. Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination. Oncoimmunology. 2012 Oct 01; 1(7):1161-1162. PMID: 23170264; PMCID: PMC3494630.
      Citations: 10     Fields:    
    361. Siefker-Radtke AO, Dinney CP, Shen Y, Williams DL, Kamat AM, Grossman HB, Millikan RE. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer. 2013 Feb 01; 119(3):540-7. PMID: 22914978; PMCID: PMC3828072.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    362. Dickstein RJ, Nitti G, Dinney CP, Davies BR, Kamat AM, McConkey DJ. Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells. Cancer Biol Ther. 2012 Nov; 13(13):1325-38. PMID: 22895070; PMCID: PMC3493441.
      Citations: 15     Fields:    Translation:HumansCells
    363. Rink M, Shariat SF, Xylinas E, Fitzgerald JP, Hansen J, Green DA, Kamat AM, Novara G, Daneshmand S, Fradet Y, Tagawa ST, Bastian PJ, Kassouf W, Trinh QD, Karakiewicz PI, Fritsche HM, Tilki D, Chun FK, Volkmer BG, Babjuk M, Merseburger AS, Scherr DS, Lotan Y, Svatek RS. Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy? World J Urol. 2012 Dec; 30(6):807-14. PMID: 22832587.
      Citations: 6     Fields:    Translation:Humans
    364. Lee EK, Herr HW, Dickstein RJ, Kassouf W, Munsell MF, Grossman HB, Dinney CP, Kamat AM. Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy. BJU Int. 2012 Dec; 110(11 Pt B):E590-5. PMID: 22758775.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    365. Jinesh GG, Lee EK, Tran J, Kamat AM. Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in vivo. Urol Oncol. 2013 Nov; 31(8):1676-1682. PMID: 22717623; PMCID: PMC5215577.
      Citations: 8     Fields:    Translation:AnimalsCells
    366. Wei H, Kamat A, Chen M, Ke HL, Chang DW, Yin J, Grossman HB, Dinney CP, Wu X. Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Gu?rin. PLoS One. 2012; 7(6):e38533. PMID: 22701660; PMCID: PMC3373532.
      Citations: 14     Fields:    Translation:Humans
    367. Dayyani F, Pettaway CA, Kamat AM, Munsell MF, Sircar K, Pagliaro LC. Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists. Urol Oncol. 2013 Oct; 31(7):1171-7. PMID: 22534087; PMCID: PMC4131852.
      Citations: 15     Fields:    Translation:Humans
    368. Jinesh G G, Chunduru S, Kamat AM. Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-a but not through TRAIL and FasL. J Leukoc Biol. 2012 Jul; 92(1):233-44. PMID: 22517918; PMCID: PMC3382315.
      Citations: 24     Fields:    Translation:HumansCells
    369. Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, Dinney CP, Siefker-Radtke A. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. 2013 Aug; 64(2):307-13. PMID: 22564397; PMCID: PMC3815632.
      Citations: 49     Fields:    Translation:Humans
    370. Svatek RS, Rosenberg JE, Galsky MD, Lee CT, Latini DM, Bochner BH, Weizer AZ, Apolo AB, Sridhar SS, Kamat AM, Hansel D, Flaig TW, Smith ND, Lotan Y. Summary of the 6th Annual Bladder Cancer Think Tank: new directions in urologic research. Urol Oncol. 2013 Oct; 31(7):968-73. PMID: 22300756; PMCID: PMC6777555.
      Citations: 2     Fields:    Translation:Humans
    371. Kamat AM, Dickstein RJ, Messetti F, Anderson R, Pretzsch SM, Gonzalez GN, Katz RL, Khanna A, Zaidi T, Wu X, Grossman HB, Dinney CP. Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Gu?rin therapy for bladder cancer: results of a prospective trial. J Urol. 2012 Mar; 187(3):862-7. PMID: 22245325; PMCID: PMC3278506.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    372. Dickstein RJ, Kamat AM. Contemporary management of locally invasive bladder cancer. Oncology (Williston Park). 2011 Dec; 25(14):1396-405. PMID: 22329191.
      Citations: 1     Fields:    Translation:Humans
    373. Lotan Y, Amiel G, Boorjian SA, Clark PE, Droller M, Gingrich JR, Guzzo TJ, Inman BA, Kamat AM, Karsh L, Nielsen ME, Smith ND, Shariat SF, Svatek RS, Taylor JM, Bladder Cancer Think Tank, Bladder Cancer Advocacy Network. Comprehensive handbook for developing a bladder cancer cystectomy database. Urol Oncol. 2013 Aug; 31(6):812-26. PMID: 22056403.
      Citations: 5     Fields:    Translation:Humans
    374. Yeh CK, Chandrasekar B, Lin AL, Dang H, Kamat A, Zhu B, Katz MS. Cellular signals underlying ?-adrenergic receptor mediated salivary gland enlargement. Differentiation. 2012 Jan; 83(1):68-76. PMID: 22099178.
      Citations: 8     Fields:    Translation:AnimalsCells
    375. Kamat AM, Mathew P. Bladder cancer: imperatives for personalized medicine. Oncology (Williston Park). 2011 Sep; 25(10):951-8, 960. PMID: 22010395.
      Citations: 4     Fields:    Translation:Humans
    376. Garcia-Closas M, Ye Y, Rothman N, Figueroa JD, Dinney CP, Chatterjee N, Prokunina-Olsson L, Wang Z, Lin J, Real FX, Jacobs KB, Baris D, Thun M, De Vivo I, Albanes D, Purdue MP, Kogevinas M, Kamat AM, Lerner SP, Grossman HB, Gu J, Pu X, Hutchinson A, Fu YP, Burdett L, Yeager M, Tang W, Serra C, Carrato A, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G, Grubb R, Black A, Jacobs EJ, Diver WR, Gapstur SM, Weinstein SJ, Virtamo J, Hunter DJ, Caporaso N, Landi MT, Fraumeni JF, Silverman DT, Chanock SJ, Wu X, Malats N, Tard?n A, Garc?a-Closas R. A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet. 2011 Nov 01; 20(21):4282-9. PMID: 21824976; PMCID: PMC3188994.
      Citations: 51     Fields:    Translation:HumansCells
    377. Kamat AM. Is repeat transurethral resection needed for minimally invasive T1 urothelial cancer? Con. J Urol. 2011 Sep; 186(3):788-9. PMID: 21794877.
      Citations: 1     Fields:    Translation:Humans
    378. Lee EK, Dickstein RJ, Kamta AM. Imaging of urothelial cancers: what the urologist needs to know. AJR Am J Roentgenol. 2011 Jun; 196(6):1249-54. PMID: 21606285.
      Citations: 2     Fields:    Translation:Humans
    379. Svatek RS, Shariat SF, Novara G, Lerner SP, Fradet Y, Bastian PJ, Aprikian A, Karakiewicz PI, Fritsche HM, Dinney CP, Tilki D, Kamat AM, Izawa JI, Ficarra V, Lotan Y, Sagalowsky AI, Schoenberg MP, Skinner EC, Kassouf W. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urol Oncol. 2013 May; 31(4):480-6. PMID: 21478035.
      Citations: 13     Fields:    Translation:Humans
    380. Gu J, Chen M, Shete S, Amos CI, Kamat A, Ye Y, Lin J, Dinney CP, Wu X. A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for bladder cancer. Cancer Prev Res (Phila). 2011 Apr; 4(4):514-21. PMID: 21460395; PMCID: PMC3076128.
      Citations: 34     Fields:    Translation:HumansCells
    381. Kamat AM, Karam JA, Grossman HB, Kader AK, Munsell M, Dinney CP. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int. 2011 Oct; 108(7):1119-23. PMID: 21426474.
      Citations: 21     Fields:    Translation:HumansPHPublic Health
    382. Parikh S, Grossman HB, Katz R, Matin SF, Dinney CP, Kamat AM, Fern?ndez MI. The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. Urol Oncol. 2012 Nov-Dec; 30(6):821-4. PMID: 21396845; PMCID: PMC3931457.
      Citations: 10     Fields:    Translation:Humans
    383. Rajput MZ, Kamat AM, Clavell-Hernandez J, Siefker-Radtke AO, Grossman HB, Dinney CP, Matin SF. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Urology. 2011 Jul; 78(1):61-7. PMID: 21354598; PMCID: PMC3118266.
      Citations: 16     Fields:    Translation:Humans
    384. Svatek RS, Shariat SF, Novara G, Skinner EC, Fradet Y, Bastian PJ, Kamat AM, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Dinney CP. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int. 2011 Mar; 107(6):898-904. PMID: 21244604.
      Citations: 49     Fields:    Translation:Humans
    385. Tran MN, Goodwin Jinesh G, McConkey DJ, Kamat AM. Bladder cancer stem cells. Curr Stem Cell Res Ther. 2010 Dec; 5(4):387-95. PMID: 20955163.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    386. Momoh AO, Kamat AM, Butler CE. Reconstruction of the pelvic floor with human acellular dermal matrix and omental flap following anterior pelvic exenteration. J Plast Reconstr Aesthet Surg. 2010 Dec; 63(12):2185-7. PMID: 20399719.
      Citations: 4     Fields:    Translation:Humans
    387. Davis JW, Gaston K, Anderson R, Dinney CP, Grossman HB, Munsell MF, Kamat AM. Robot assisted extended pelvic lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection. J Urol. 2011 Jan; 185(1):79-83. PMID: 21074799.
      Citations: 15     Fields:    Translation:Humans
    388. Metwalli AR, Khanbolooki S, Jinesh G, Sundi D, Shah JB, Shrader M, Choi W, Lashinger LM, Chunduru S, McConkey DJ, McKinlay M, Kamat AM. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biol Ther. 2010 Nov 01; 10(9):885-92. PMID: 20814238; PMCID: PMC3230293.
      Citations: 17     Fields:    Translation:HumansCells
    389. Caraway NP, Khanna A, Fernandez RL, Payne L, Bassett RL, Zhang HZ, Kamat A, Katz RL. Fluorescence in situ hybridization for detecting urothelial carcinoma: a clinicopathologic study. Cancer Cytopathol. 2010 Oct 25; 118(5):259-68. PMID: 20665656; PMCID: PMC2993817.
      Citations: 19     Fields:    Translation:Humans
    390. Shah JB, Kamat AM. Fluorescence cystoscopy for nonmuscle invasive bladder cancer: is the honeymoon over for the blue light special? Cancer. 2011 Mar 01; 117(5):882-3. PMID: 20960505.
      Citations:    Fields:    Translation:Humans
    391. Xu AD, Ng CS, Kamat A, Grossman HB, Dinney C, Sandler CM. Significance of upper urinary tract urothelial thickening and filling defect seen on MDCT urography in patients with a history of urothelial neoplasms. AJR Am J Roentgenol. 2010 Oct; 195(4):959-65. PMID: 20858825.
      Citations: 10     Fields:    Translation:Humans
    392. Sundi D, Svatek RS, Margulis V, Wood CG, Matin SF, Dinney CP, Kamat AM. Upper tract urothelial carcinoma: impact of time to surgery. Urol Oncol. 2012 May-Jun; 30(3):266-72. PMID: 20869888; PMCID: PMC3034106.
      Citations: 17     Fields:    Translation:Humans
    393. Chen M, Hildebrandt MA, Clague J, Kamat AM, Picornell A, Chang J, Zhang X, Izzo J, Yang H, Lin J, Gu J, Chanock S, Kogevinas M, Rothman N, Silverman DT, Garcia-Closas M, Grossman HB, Dinney CP, Wu X, Malats N. Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. Cancer Prev Res (Phila). 2010 Oct; 3(10):1235-45. PMID: 20858759; PMCID: PMC2955764.
      Citations: 28     Fields:    Translation:Humans
    394. Kamat AM. To the editor: response to Barlow et al, Urol Oncol 2010. Urol Oncol. 2013 Jan; 31(1):124. PMID: 20822931.
      Citations:    Fields:    Translation:Humans
    395. Matin SF, Kamat AM, Grossman HB. High-frequency endoluminal ultrasonography as an aid to the staging of upper tract urothelial carcinoma: imaging findings and pathologic correlation. J Ultrasound Med. 2010 Sep; 29(9):1277-84. PMID: 20733182.
      Citations: 9     Fields:    Translation:Humans
    396. Matin SF, Margulis V, Kamat A, Wood CG, Grossman HB, Brown GA, Dinney CP, Millikan R, Siefker-Radtke AO. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer. 2010 Jul 01; 116(13):3127-34. PMID: 20564621.
      Citations: 59     Fields:    Translation:Humans
    397. Karam JA, Kamat AM. Optimal timing of chemotherapy and cystectomy. F1000 Med Rep. 2010 Jun 23; 2. PMID: 20948836; PMCID: PMC2950042.
      Citations: 1     
    398. Kamat AM, Zlotta A, Bochner BH, Moore R, So A, Izawa J, Rendon RA, Lacombe L, Aprikian AG, Kassouf W. Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy. Can Urol Assoc J. 2010 Jun; 4(3):168-73. PMID: 20514279; PMCID: PMC2874590.
      Citations: 18     
    399. Svatek RS, Fisher MB, Williams MB, Matin SF, Kamat AM, Grossman HB, Urbauer DL, Dinney CP, Nogueras-Gonz?lez GM. Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy. Urology. 2010 Dec; 76(6):1419-24. PMID: 20472264.
      Citations: 33     Fields:    Translation:Humans
    400. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010 May 15; 16(10):2861-71. PMID: 20460488; PMCID: PMC2919850.
      Citations: 186     Fields:    Translation:HumansCellsCTClinical Trials
    401. Robinson VL, Porter M, Messing E, Fradet Y, Kamat AM, Lotan Y. BCAN Think Tank session 2: Molecular detection of bladder cancer: the path to progress. Urol Oncol. 2010 May-Jun; 28(3):334-7. PMID: 20439033.
      Citations: 2     Fields:    Translation:Humans
    402. Lerner SP, Grossman HB, Messing EM, Kibel AS, Stephenson A, Gee JR, O'Donnell MA, Reid RD, Kamat AM, Parnes HL, House MG. BCAN Think Tank session 3: Prevention of bladder cancer. Urol Oncol. 2010 May-Jun; 28(3):338-42. PMID: 20439034.
      Citations: 3     Fields:    Translation:Humans
    403. Black PC, Dinney CP, Brown GA, Kassouf W, Siefker-Radtke AO, Munsell MF, Grossman HB, Kamat AM. The role of radical cystectomy in patients with clinical T4b bladder cancer. Urol Oncol. 2011 Mar-Apr; 29(2):157-61. PMID: 20456984; PMCID: PMC2950900.
      Citations: 5     Fields:    Translation:Humans
    404. Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Kassouf W, Novara G, Fritsche HM, Izawa JI, Ficarra V, Lerner SP, Sagalowsky AI, Schoenberg MP, Kamat AM, Dinney CP, Lotan Y, Marberger MJ, Fradet Y. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int. 2010 May; 105(10):1402-12. PMID: 20132195.
      Citations: 41     Fields:    Translation:Humans
    405. Svatek RS, Fisher MB, Matin SF, Kamat AM, Grossman HB, Urbauer DL, Kennedy KA, Dinney CP, Nogueras-Gonz?lez GM. Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria. J Urol. 2010 Mar; 183(3):929-34. PMID: 20083264.
      Citations: 22     Fields:    Translation:Humans
    406. Inamoto T, Czerniak BA, Dinney CP, Kamat AM. Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer. Cancer. 2010 Jan 15; 116(2):340-6. PMID: 19908257.
      Citations: 31     Fields:    Translation:HumansCells
    407. Kamat AM, Lotan YR. Perioperative intravesical therapy after transurethral resection for bladder cancer. J Urol. 2010 Jan; 183(1):19-20. PMID: 19913827.
      Citations: 1     Fields:    Translation:Humans
    408. Cho SD, Lee SO, Chintharlapalli S, Abdelrahim M, Khan S, Yoon K, Kamat AM, Safe S. Activation of nerve growth factor-induced B alpha by methylene-substituted diindolylmethanes in bladder cancer cells induces apoptosis and inhibits tumor growth. Mol Pharmacol. 2010 Mar; 77(3):396-404. PMID: 20023005; PMCID: PMC2835419.
      Citations: 36     Fields:    Translation:HumansAnimalsCells
    409. Taylor JM, Spiess PE, Kassouf W, Munsell MF, Kamat AM, Dinney CP, Grossman HB, Pisters LL. Management of urethral recurrence after orthotopic urinary diversion. BJU Int. 2010 Jul; 106(1):56-61. PMID: 20002676.
      Citations: 7     Fields:    Translation:Humans
    410. McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, Siefker-Radtke A, Dinney C. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 2009 Dec; 28(3-4):335-44. PMID: 20012924; PMCID: PMC5915353.
      Citations: 176     Fields:    Translation:HumansCells
    411. Kamat AM, Tharakan ST, Sung B, Aggarwal BB. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res. 2009 Dec 01; 69(23):8958-66. PMID: 19903839.
      Citations: 45     Fields:    Translation:HumansAnimalsCells
    412. Davis JW, Kamat A, Munsell M, Pettaway C, Pisters L, Matin S. Initial experience of teaching robot-assisted radical prostatectomy to surgeons-in-training: can training be evaluated and standardized? BJU Int. 2010 Apr; 105(8):1148-54. PMID: 19874300.
      Citations: 12     Fields:    Translation:Humans
    413. Chiong E, Hegarty PK, Davis JW, Kamat AM, Pisters LL, Matin SF. Port-site hernias occurring after the use of bladeless radially expanding trocars. Urology. 2010 Mar; 75(3):574-80. PMID: 19854489.
      Citations: 22     Fields:    Translation:Humans
    414. Kamat AM, Svatek R. Editorial comment. J Urol. 2009 Dec; 182(6):2630; discussion 2631. PMID: 19836780.
      Citations:    Fields:    Translation:Humans
    415. Fisher MB, Svatek RS, Hegarty PK, McGinniss JE, Hightower C, Grossman HB, Kamat AM, Dinney CP, Matin SF. Cardiac history and risk of post-cystectomy cardiac complications. Urology. 2009 Nov; 74(5):1085-9. PMID: 19758689; PMCID: PMC2784244.
      Citations: 3     Fields:    Translation:Humans
    416. Kamat AM. Editorial comment. J Urol. 2009 Nov; 182(5):2203. PMID: 19758663.
      Citations:    Fields:    Translation:Humans
    417. Lotan Y, Kamat AM, Porter MP, Robinson VL, Shore N, Jewett M, Schelhammer PF, deVere White R, Quale D, Lee CT, Bladder Cancer Think Tank, Bladder Cancer Advocacy Network, Society of Urologic Oncology. Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. Cancer. 2009 Sep 15; 115(18):4096-103. PMID: 19536899.
      Citations: 20     Fields:    Translation:Humans
    418. Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, Otto W, Capitanio U, Izawa JI, Ficarra V, Lerner S, Sagalowsky AI, Schoenberg M, Kamat A, Dinney CP, Lotan Y, Shariat SF. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol. 2010 Feb; 57(2):300-9. PMID: 19766384.
      Citations: 47     Fields:    Translation:Humans
    419. Kulkarni GS, Hakenberg OW, Gschwend JE, Thalmann G, Kassouf W, Kamat A, Zlotta A. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol. 2010 Jan; 57(1):60-70. PMID: 19740595.
      Citations: 50     Fields:    Translation:Humans
    420. Tharakan ST, Inamoto T, Sung B, Aggarwal BB, Kamat AM. Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers. Biochem Pharmacol. 2010 Jan 15; 79(2):218-28. PMID: 19682434; PMCID: PMC3181149.
      Citations: 23     Fields:    Translation:HumansCells
    421. Lin J, Kamat A, Gu J, Chen M, Dinney CP, Forman MR, Wu X. Dietary intake of vegetables and fruits and the modification effects of GSTM1 and NAT2 genotypes on bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2009 Jul; 18(7):2090-7. PMID: 19549811.
      Citations: 20     Fields:    Translation:HumansAnimals
    422. Martin FM, Kamat AM. Definition and management of patients with bladder cancer who fail BCG therapy. Expert Rev Anticancer Ther. 2009 Jun; 9(6):815-20. PMID: 19496718.
      Citations: 11     Fields:    Translation:Humans
    423. Svatek RS, Kamat AM, Dinney CP. Novel therapeutics for patients with non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2009 Jun; 9(6):807-13. PMID: 19496717.
      Citations: 1     Fields:    Translation:Humans
    424. Guo CC, Gomez E, Tamboli P, Bondaruk JE, Kamat A, Bassett R, Dinney CP, Czerniak BA. Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases. Hum Pathol. 2009 Oct; 40(10):1448-52. PMID: 19454359.
      Citations: 14     Fields:    Translation:Humans
    425. Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, Dinney CP, Millikan RE. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol. 2009 Jun 01; 27(16):2592-7. PMID: 19414678; PMCID: PMC4879720.
      Citations: 48     Fields:    Translation:HumansCTClinical Trials
    426. Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG, Upper Tract Urothelial Carcinoma CollaborationThe Upper Tract Urothelial Carcinoma Collaboration. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009 Mar 15; 115(6):1224-33. PMID: 19156917.
      Citations: 290     Fields:    Translation:Humans
    427. Svatek RS, Spiess PE, Sundi D, Tu SM, Tannir NM, Brown GA, Kamat AM, Wood CG, Pisters LL. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer. 2009 Mar 15; 115(6):1310-7. PMID: 19156903.
      Citations: 3     Fields:    Translation:Humans
    428. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, Sharma P. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A. 2009 Feb 24; 106(8):2729-34. PMID: 19202079; PMCID: PMC2650334.
      Citations: 99     Fields:    Translation:HumansCells
    429. Inamoto T, Shah JB, Kamat AM. Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer. Urol Oncol. 2009 Nov-Dec; 27(6):585-91. PMID: 19162510.
      Citations: 7     Fields:    Translation:HumansAnimals
    430. Hegarty PK, Kamat AM. Management of bladder cancer. Minerva Urol Nefrol. 2008 Dec; 60(4):255-64. PMID: 18923362.
      Citations:    Fields:    Translation:Humans
    431. Inamoto T, Papineni S, Chintharlapalli S, Cho SD, Safe S, Kamat AM. 1,1-Bis(3'-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth. Mol Cancer Ther. 2008 Dec; 7(12):3825-33. PMID: 19074857; PMCID: PMC4948978.
      Citations: 46     Fields:    Translation:HumansAnimalsCells
    432. La Rochelle J, Kamat A, Grossman HB, Pantuck A. Chemoprevention of bladder cancer. BJU Int. 2008 Nov; 102(9 Pt B):1274-8. PMID: 19035892.
      Citations: 2     Fields:    Translation:Humans
    433. Kassouf W, Agarwal PK, Grossman HB, Leibovici D, Munsell MF, Siefker-Radtke A, Pisters LL, Swanson DA, Dinney CP, Kamat AM. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology. 2009 Jan; 73(1):147-52. PMID: 18848348; PMCID: PMC2674246.
      Citations: 21     Fields:    Translation:Humans
    434. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C, Sharma P. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A. 2008 Sep 30; 105(39):14987-92. PMID: 18818309; PMCID: PMC2567480.
      Citations: 238     Fields:    Translation:HumansCells
    435. Kamat AM. Intravesical BCG for bladder cancer: how much is enough? Cancer. 2008 Aug 15; 113(4):674-6. PMID: 18543323.
      Citations:    Fields:    Translation:Humans
    436. Kassouf W, Spiess PE, Brown GA, Liu P, Grossman HB, Dinney CP, Kamat AM. Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction. J Urol. 2008 Jul; 180(1):164-7; discussion 167. PMID: 18485384; PMCID: PMC5154171.
      Citations: 11     Fields:    Translation:Humans
    437. Cooksley C, Kamat AM, Pettaway CA, Elting LS, C?rdenas-Turanzas M. Gender and age differences in blood utilization and length of stay in radical cystectomy: a population-based study. Int Urol Nephrol. 2008; 40(4):893-9. PMID: 18317944.
      Citations: 8     Fields:    Translation:Humans
    438. Spiess PE, Pisters LL, Liu P, Pettaway CA, Kamat AM, Gomez JA, Tannir NM. Malignant transformation of testicular teratoma: a chemoresistant phenotype. Urol Oncol. 2008 Nov-Dec; 26(6):595-9. PMID: 18367105; PMCID: PMC4121060.
      Citations: 10     Fields:    Translation:Humans
    439. Agarwal PK, Kamat AM. Pros and cons of radical cystectomy in the treatment of T1G3 bladder cancer. Indian J Urol. 2008 Jan; 24(1):77-83. PMID: 19468365; PMCID: PMC2684254.
      Citations: 1     
    440. Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 01; 14(1):224-9. PMID: 18172274.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    441. Kassouf W, Agarwal PK, Herr HW, Munsell MF, Spiess PE, Brown GA, Pisters L, Grossman HB, Dinney CP, Kamat AM. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol. 2008 Jan 01; 26(1):121-6. PMID: 18165646.
      Citations: 43     Fields:    Translation:Humans
    442. Agarwal PK, Black PC, Kamat AM. Considerations on the use of diagnostic markers in management of patients with bladder cancer. World J Urol. 2008 Feb; 26(1):39-44. PMID: 18092171.
      Citations: 7     Fields:    Translation:HumansPHPublic Health
    443. Spiess PE, Tannir NM, Tu SM, Brown GA, Liu P, Kamat AM, Wood CG, Evans JG, Pisters LL. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer. 2007 Dec 15; 110(12):2700-8. PMID: 17948916.
      Citations: 4     Fields:    Translation:Humans
    444. Caraway NP, Khanna A, Payne L, Kamat AM, Katz RL. Combination of cytologic evaluation and quantitative digital cytometry is reliable in detecting recurrent disease in patients with urinary diversions. Cancer. 2007 Oct 25; 111(5):323-9. PMID: 17721991.
      Citations: 5     Fields:    Translation:Humans
    445. Wright JL, Black PC, Brown GA, Porter MP, Kamat AM, Dinney CP, Lin DW. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol. 2007 Dec; 178(6):2302-6; discussion 2307. PMID: 17936803.
      Citations: 43     Fields:    Translation:Humans
    446. Chen M, Kamat AM, Huang M, Grossman HB, Dinney CP, Lerner SP, Wu X, Gu J. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis. 2007 Oct; 28(10):2160-5. PMID: 17728339.
      Citations: 29     Fields:    Translation:HumansCells
    447. Kassouf W, Spiess PE, Siefker-Radtke A, Swanson D, Grossman HB, Kamat AM, Munsell MF, Guo CC, Czerniak BA, Dinney CP. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer. 2007 Aug 15; 110(4):764-9. PMID: 17614317.
      Citations: 33     Fields:    Translation:Humans
    448. Brown GA, Matin SF, Busby JE, Dinney CP, Grossman HB, Pettaway CA, Munsell MF, Kamat AM. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology. 2007 Aug; 70(2):252-6. PMID: 17826484; PMCID: PMC2034451.
      Citations: 27     Fields:    Translation:Humans
    449. Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL, Pisters LL. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer. 2007 Jul 01; 110(1):62-7. PMID: 17542024.
      Citations: 59     Fields:    Translation:Humans
    450. Jhamb M, Lin J, Ballow R, Kamat AM, Grossman HB, Wu X. Urinary tract diseases and bladder cancer risk: a case-control study. Cancer Causes Control. 2007 Oct; 18(8):839-45. PMID: 17593531.
      Citations: 11     Fields:    Translation:Humans
    451. Kamat AM, Fisher MB. Lymph node density: surrogate marker for quality of resection in bladder cancer? Expert Rev Anticancer Ther. 2007 Jun; 7(6):777-9. PMID: 17555386.
      Citations: 1     Fields:    Translation:Humans
    452. Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Siefker-Radtke A, Dinney CP, Kamat AM. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol. 2007 Sep; 52(3):769-74. PMID: 17434254; PMCID: PMC2691552.
      Citations: 14     Fields:    Translation:Humans
    453. Spiess PE, Kassouf W, Brown GA, Kamat AM, Liu P, Gomez JA, Tu SM, Tannir NM, Pisters LL. Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urol. 2007 Apr; 177(4):1330-4; discussion 1334. PMID: 17382725.
      Citations: 26     Fields:    Translation:Humans
    454. Kamat AM, Wu X. Statins and the effect of BCG on bladder cancer. N Engl J Med. 2007 Mar 22; 356(12):1276; author reply 1276-7. PMID: 17377172.
      Citations: 6     Fields:    Translation:Humans
    455. Kamat AM, Sethi G, Aggarwal BB. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol Cancer Ther. 2007 Mar; 6(3):1022-30. PMID: 17363495.
      Citations: 60     Fields:    Translation:HumansCells
    456. Spiess PE, Brown GA, Liu P, Tu SM, Tannir NM, Evans JG, Kamat AM, Kassouf W, Pisters LL. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2007 Jan; 177(1):131-8. PMID: 17162023.
      Citations:    Fields:    Translation:HumansPHPublic Health
    457. Spiess PE, Kassouf W, Steinberg JR, Tuziak T, Hernandez M, Tibbs RF, Czerniak B, Kamat AM, Dinney CP, Grossman HB. Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol. 2007 Jan-Feb; 25(1):38-45. PMID: 17208137.
      Citations: 19     Fields:    Translation:Humans
    458. Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, Matin SF. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int. 2006 Dec; 98(6):1176-80. PMID: 17125474.
      Citations: 30     Fields:    Translation:Humans
    459. Papageorgiou A, Kamat A, Benedict WF, Dinney C, McConkey DJ. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther. 2006 Dec; 5(12):3032-41. PMID: 17172406.
      Citations: 15     Fields:    Translation:HumansAnimals
    460. Busby JE, Kamat AM. Chemoprevention for bladder cancer. J Urol. 2006 Nov; 176(5):1914-20. PMID: 17070211.
      Citations: 10     Fields:    Translation:Humans
    461. Brassell SA, Kamat AM. Contemporary intravesical treatment options for urothelial carcinoma of the bladder. J Natl Compr Canc Netw. 2006 Nov; 4(10):1027-36. PMID: 17112451.
      Citations: 3     Fields:    Translation:Humans
    462. Kassouf W, Leibovici D, Luongo T, Munsell MF, Vakar F, Dinney CP, Grossman HB, Kamat AM. Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. Cancer. 2006 Oct 01; 107(7):1491-5. PMID: 16894527.
      Citations: 5     Fields:    Translation:Humans
    463. Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, Czerniak B, Kamat AM, Pisters LL. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer. 2006 Oct 01; 107(7):1483-90. PMID: 16944541.
      Citations: 7     Fields:    Translation:Humans
    464. Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, Kamat AM, Black P, Tannir NM. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Cancer. 2006 Oct 01; 107(7):1503-10. PMID: 16944534.
      Citations: 7     Fields:    Translation:Humans
    465. Evans JG, Spiess PE, Kamat AM, Wood CG, Hernandez M, Pettaway CA, Dinney CP, Pisters LL. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J Urol. 2006 Oct; 176(4 Pt 1):1463-7. PMID: 16952661.
      Citations: 27     Fields:    Translation:Humans
    466. Kassouf W, Highshaw R, Nelkin GM, Dinney CP, Kamat AM. Vitamins C and K3 sensitize human urothelial tumors to gemcitabine. J Urol. 2006 Oct; 176(4 Pt 1):1642-7. PMID: 16952707.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    467. Kamat AM, Dinney CP. A combination of intravesical BCG [corrected] and [corrected] electromotive mitomycin for high-risk superficial bladder cancer. Nat Clin Pract Urol. 2006 Sep; 3(9):472-3. PMID: 16964186.
      Citations:    Fields:    
    468. Metwalli AR, Kamat AM. Controversial issues and optimal management of stage T1G3 bladder cancer. Expert Rev Anticancer Ther. 2006 Aug; 6(8):1283-94. PMID: 16925494.
      Citations: 3     Fields:    Translation:Humans
    469. Strom SS, Kamat AM, Gruschkus SK, Gu Y, Wen S, Cheung MR, Pisters LL, Lee AK, Rosser CJ, Kuban DA. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer. 2006 Aug 01; 107(3):631-9. PMID: 16802288.
      Citations: 23     Fields:    Translation:Humans
    470. Rosser CJ, Kamat AM, Pendleton J, Robinson TL, Pisters LL, Swanson DA, Babaian RJ. Impact of fellowship training on pathologic outcomes and complication rates of radical prostatectomy. Cancer. 2006 Jul 01; 107(1):54-9. PMID: 16708356.
      Citations: 12     Fields:    Translation:Humans
    471. Kassouf W, Leibovici D, Munsell MF, Dinney CP, Grossman HB, Kamat AM. Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol. 2006 Jul; 176(1):53-7; discussion 57. PMID: 16753366.
      Citations: 27     Fields:    Translation:Humans
    472. Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF, Grossman HB, Dinney CP. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol. 2006 Jun; 175(6):2058-62. PMID: 16697803.
      Citations: 32     Fields:    Translation:Humans
    473. Rosser CJ, Kamat AM, Wang X, Do KA, Naya Y, Hoover DC, Troncoso P, Sanches-Ortiz RF, Pisters LL. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with radical prostatectomy. Urology. 2006 Apr; 67(4):769-73. PMID: 16584762.
      Citations: 2     Fields:    Translation:Humans
    474. Spiess PE, Kassouf W, Brown G, Highshaw R, Wang X, Do KA, Kamat AM, Czerniak B, Dinney CP, Grossman HB. Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach? Urology. 2006 Mar; 67(3):466-71. PMID: 16527559.
      Citations: 4     Fields:    Translation:Humans
    475. Kamat AM, Gee JR, Dinney CP, Grossman HB, Swanson DA, Millikan RE, Detry MA, Robinson TL, Pisters LL. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol. 2006 Mar; 175(3 Pt 1):881-5. PMID: 16469571.
      Citations: 45     Fields:    Translation:Humans
    476. Busby JE, Brown GA, Tamboli P, Kamat AM, Dinney CP, Grossman HB, Matin SF. Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology. 2006 Mar; 67(3):518-23. PMID: 16527570.
      Citations: 21     Fields:    Translation:Humans
    477. Canfield SE, Kamat AM, Detry M, Swanson DA, Wood CG, S?nchez-Ortiz RF. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol. 2006 Mar; 175(3 Pt 1):864-9. PMID: 16469567.
      Citations: 21     Fields:    Translation:Humans
    478. Bommireddy R, Kamat A, Smith ET, Nixon T, Pillay R, Pigott T, Findlay GF. Magnetic resonance image findings in the early post-operative period after anterior cervical discectomy. Eur Spine J. 2007 Jan; 16(1):27-31. PMID: 16421746; PMCID: PMC2198885.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    479. Kassouf W, Chintharlapalli S, Abdelrahim M, Nelkin G, Safe S, Kamat AM. Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Res. 2006 Jan 01; 66(1):412-8. PMID: 16397256.
      Citations: 36     Fields:    Translation:HumansAnimals
    480. Kamat AM, Nelkin GM. Atorvastatin: a potential chemopreventive agent in bladder cancer. Urology. 2005 Dec; 66(6):1209-12. PMID: 16360444.
      Citations: 12     Fields:    Translation:HumansCells
    481. Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, Pisters LL. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol. 2005 Dec; 174(6):2186-90. PMID: 16280761.
      Citations: 13     Fields: